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ABSTRACT 
 
 
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by 
synovial inflammation and joint deformity. The pathogenesis of RA is mediated by several 
immune cells (such as monocytes, granulocytes, T and B lymphocytes) that infiltrate the 
synovial membrane and secrete a complex network of pro-inflammatory cytokines, 
chemokines and other inflammatory mediators, which perpetuate the inflammatory process 
associated with bone resorption and damage. RA remains an incurable, progressive and 
debiliting disease for the great majority of patients despite profound evolution of the 
therapeutics options over the last decades. Indeed, the new biotechnological treatments for 
RA are administered parenterally, have safety issues and constitute a significant economic 
burden to national health services. Thus, the development of therapeutic strategies able to 
control both synovial inflammation and bone erosion, with a high rate of disease remission, 
low incidence of side effects and low production costs is still an unmet medical need in RA. 
Celastrol, a bioactive component of the Chinese herb Tripterygium wilfordii, has shown 
significant anti-inflammatory properties in vitro and in vivo, mainly attributed to the 
regulation of cytokine and chemokine production, the inhibition of cell invasion and 
proliferation, osteoclast modulation and suppression of bone resorption. Our group has 
previously characterized the efficacy and safety of celastrol in an animal model of arthritis, 
showing a reduction of synovial leukocyte infiltration. 
The main goal of this work was to analyze the effect of celastrol with or without LPS 
stimulation on primary human leukocytes (such as monocytes, granulocytes, T and B cells 
and their subsets) activation, maturation, survival and apoptosis using peripheral blood 
samples collected from chronic RA patients (with more than 1 year of disease duration) in 
comparison with healthy controls, using Flow Cytometry and performing alarmarBlue® cell 
vitality assay. 
For that, we first proceeded to the optimization of the experimental conditions 
(assessing the optimal compounds concentrations and incubation time to be tested), where 
peripheral leukocytes from healthy controls (n=4) were incubated at a range of celastrol 
(0,001 µM, 0,01 µM, 0,05 µM, 0,1 µM, 0,3 µM, 0,5 µM and 1 µM) and LPS (2 μg/mL, 5 
μg/mL and 10 μg/mL) concentrations, and under a varying incubation times (0h, 4h, 16h and 
24h). After incubation, cell viability was assessed using alarmarBlue® by 
spectrophotometry assay, and an immunophenotyping characterization of monocytes, 
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granulocytes, B and T cells was performed by Flow Cytometry. We found that incubation 
for 4h with celastrol 0,3 µM and LPS 10 μg/mL was the condition that showed less 
lymphocyte’s, monocyte’s and granulocyte’s cell death, appearing to be the best condition to 
be tested in the following experiments. Next, we studied the effect of celastrol in peripheral 
leukocytes of the recruited chronic RA patients (n=5) and healthy controls (n=10), using the 
pre-optimized experimental conditions. 
Our results have shown that celastrol had no significant effect on CD14+ monocytes, 
CD66b+ granulocytes, CD19+ B cell and CD3+ T cell levels, both in healthy controls and in 
chronic RA patients.  
Accordingly, the overall data about monocytes have shown that celastrol was able to 
diminish (after LPS stimulation) CD16 and CD115 frequency and expression, and restore 
HLA-DR expression and CD86 frequency and expression to basal levels in monocytes (on 
total CD14+ cells) from healthy controls. In addition, in chronic RA patients, celastrol was 
able to reduce CD115 frequency and decrease (after LPS stimulation) CD86 frequency on 
monocytes (on total CD14+ cells). 
Regarding granulocytes, our results have shown that celastrol was able to diminish 
CD62L expression and restore CD11b expression and CXCR2 frequency to basal levels in 
granulocytes (on total CD66b+ cells) from healthy controls. In chronic RA patients, 
celastrol was able to restore CD11b expression to basal levels in granulocytes (on total 
CD66b+ cells).  
Our data regarding T cells have shown that celastrol was able to increase central 
memory Th2-like cells (CXCR3-CCR6-) and effector memory Th2-like cells (CXCR3-
CCR6-) frequency and restore naïve activated T helper cells (CD45RO-HLA-DR+) 
frequency to basal levels from healthy controls. In chronic RA patients, celastrol was able 
to increase memory activated T helper cells (CD45RO+HLA-DR+) frequency. Moreover, 
our results have shown that celastrol was able to reduce (after LPS stimulation) CXCR3 
expression to basal levels in T cells (on total CD3+ cells and on T helper cells 
(CD3+CD4+)) from healthy controls. 
Concerning B cells, our findings have shown that celastrol was able to diminish 
RANKL and CD95 frequency on transitional B cells (IgD+CD38++) and CD95 expression 
on naïve B cells (IgD+CD27-) and transitional B cells (IgD+CD38++) from healthy 
controls. In addition, celastrol was able to restore RANKL frequency to basal levels in B 
cells (on total CD19+ B cells, naïve (IgD+CD27-), pre-switch memory (IgD+CD27+), post-
switch memory (IgD-CD27+) B cells)) from healthy controls. Also, in healthy controls, 
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celastrol was able to restore CD95 frequency and expression and FcgRIIB expression to 
basal levels in B cells (on plasmablasts (IgD-CD38++); restore CD95 frequency and CD21 
expression to basal levels on naïve B cells (IgD+CD27-) and CD21 expression to basal 
levels in B cells (on total CD19+ B cells); and restore (after LPS stimulation) HLA-DR 
frequency to basal levels in B cells (on transitional B cells (IgD+CD38++). 
Celastrol seems to have a stronger effect on innate immune system cells, reducing their 
overall activation, differentiation and migration potential.  
Accordingly, celastrol is a promising candidate for further testing in the clinic for RA 
therapy. Furthermore, the results suggest that celastrol might also be beneficial for the 
treatment of a few other autoimmune diseases besides arthritis. 
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RESUMO 
 
 
A artrite reumatóide (AR) é uma doença progressiva autoimune caracterizada por 
inflamação crónica sinovial e deformação irreversível das articulações, que pode levar à 
destruição da cartilagem e erosão óssea, causando incapacidade funcional e redução da 
esperança média de vida do doente, se não for devidamente e precocemente tratada. 
Inicialmente, manifesta-se através de inchaço, dor e rigidez das pequenas articulações das 
mãos, alastrando-se progressivamente para as articulações maiores dos joelhos e tornozelos. 
Deste modo, o diagnóstico e tratamento precoce e adequado é essencial para prevenir a 
progressão da doença e a destruição óssea e articular a ela associada.  
O processo inflamatório da AR é caracterizado pelo recrutamento de células imunitárias 
(leucócitos) da circulação sanguínea periférica para o líquido e tecido sinovial. Nesta patologia 
estão envolvidas células imunitárias tanto do sistema imunitário inato (macrófagos e 
neutrófilos) como do adaptativo (linfócitos B e T), que infiltram a membrana sinovial (que 
reveste as articulações) e secretam citocinas pro-inflamatórias – particularmente as 
interleucinas (IL)-1β, IL-6 e IL-17 e o factor de necrose tumoral (TNF) – , quimiocinas e 
outros mediadores inflamatórios, tornando-a hiperplásica. Assim, o tecido sinovial torna-se, 
maioritariamente, repleto de macrófagos e linfócitos (células B e T), enquanto que o líquido 
sinovial é concentrado com neutrófilos.  
As interações entre células apresentadoras de antigénios (APCs), células T e células B 
activam a resposta imunitária, levando à produção de autoanticorpos e excessiva activação de 
células T. Subsequentemente, estas células T activadas vão continuamente activar monócitos, 
macrófagos e fibroblastos sinoviais, induzindo a produção de citocinas pro-inflamatórias e 
quimiocinas que perpetuam o processo inflamatório, bem como mediadores de actividade 
óssea e enzimas com capacidade de reabsorver e destruir cartilagem e osso. 
Monócitos/macrófagos (precursores de osteoclastos) são induzidos a expressar RANK, que 
após se ligar ao seu ligando, RANKL, secretado pelos osteoblastos, estimula a sua 
diferenciação em osteoclastos maduros, responsáveis pela reabsorção e erosão óssea na AR. 
A AR é uma doença de etiologia desconhecida e que afecta cerca de 0,5% a 1% da 
população mundial, sendo mais frequente nas mulheres (≈75%). Apesar da profunda evolução 
das opções terapêuticas ao longo das últimas décadas, a AR continua a ser uma doença 
incurável, progressiva e debilitante para a grande maioria dos doentes. O objectivo do 
tratamento na AR é a remissão, que é alcançada apenas em 20% - 30% dos doentes, se 
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precocemente e adequadamente tratados, no entanto, a maioria experiencia efeitos colaterais 
graves. Os primeiros tratamentos administrados aos doentes com AR são glucocorticóides, 
úteis no alívio dos sintomas clínicos e na diminuição da inflamação. Contudo, por terem 
efeitos secundários adversos em doses elevadas, são substituídos, numa segunda fase por 
drogas antirreumáticas modificadoras da doença (csDMARDs) sintécticas convencionais, que 
incluem o metrotexato (MTX), o fármaco mais usado no tratamento da AR e eficaz no controlo 
da actividade e progressão da doença. Ainda assim, uma grande percentagem de doentes é não-
respondedora ou deixa de responder ao tratamento, pelo que a introdução de terapias 
biológicas (bDMARDs), como agentes anti- TNF, IL-1β, IL6, células B e T, têem surgido 
como uma alternativa aos convencionais DMARDs. Mais recentemente, têem também sido 
desenvolvidos agentes inibidores que são pequenas moléculas (tsDMARDs), como o 
tofacitinib, que apesar de inovadoras, infelizmente são terapias excessivamente caras, 
limitando o acesso aos serviços de saúde. Para além disso, muitas destas terapias são apenas 
eficazes no controlo da inflamação ou no do dano ósseo, pelo que para alguns doentes 
nenhuma destas terapias é eficaz. Assim, o desenvolvimento de estratégias terapêuticas 
capazes de controlar tanto a inflamação sinovial como a erosão óssea, com uma elevada taxa 
de remissão da doença, baixa incidência de efeitos colaterais e baixos custos de produção ainda 
é uma necessidade médica não atendida na AR.  
O celastrol, um componente bioactivo extraído da planta chinesa Tripterygium wilfordii, 
que tem sido muito usado na medicina Chinesa para tratar inflamação e doenças auto-imunes 
incluindo a AR, foi previamente identificado pelo nosso grupo como um potencial candidato 
terapêutico para a AR, por inibir simultaneamente a produção das citocinas pro-inflamatórias 
TNF e IL-1β, directamente relacionadas com a inflamação e a degradação óssea na AR. Vários 
estudos têem apontado significantes propriedades anti-inflamatórias do celastrol in vitro e in 
vivo, maioritariamente atribuídas à regulação da produção de citocinas e quimiocinas, à 
inibição da invasão/infiltração e proliferação celular, modulação de osteoclastos e supressão da 
reabsorção óssea. Particularmente, o nosso grupo tem determinado a eficácia e segurança do 
celastrol num modelo animal de artrite, mostrando uma redução da infiltração leucocitária 
sinovial.  
Assim, o principal objectivo deste trabalho foi avaliar o efeito do celastrol, com ou sem 
estimulação de LPS, na activação, maturação, sobrevivência e apoptose de leucócitos humanos 
primários (monócitos, granulócitos, células B e T e suas subpopulações), utilizando amostras 
de sangue periférico recolhidas de doentes com AR crónica (com mais de 1 ano de duração de 
doença) em comparação com controlos saudáveis, recorrendo à técnica de Citometria de Fluxo 
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e ao ensaio de viabilidade alamarBlue®.  
Para isso, primeiramente procedemos à optimização das condições experimentais (com 
vista à determinação das concentrações ideais de compostos e tempo de incubação a testar), 
onde leucócitos periféricos de controlos saudáveis (n=4) foram incubados numa gama de 
concentrações de celastrol (0,001 µM, 0,01 µM, 0,05 µM, 0,1 µM, 0,3 µM, 0,5 µM e 1 µM) e 
LPS (2 μg/mL, 5 μg/mL e 10 μg/mL), e sob tempos de incubação variáveis (0h, 4h, 16h e 24h). 
Após cada incubação, a viabilidade celular foi determinada usando o reagente de alamarBlue® 
através de um ensaio de espectrofotometria, e a caracterização imunofenotípica dos monócitos, 
granulócitos, células B e T, foi realizada por Citometria de Fluxo. De entre as condições 
testadas, verificou-se que a incubação de 4h com 0,3 µM de celastrol e 10 µg/mL de LPS foi a 
condição que apresentou menos morte celular das populações de linfócitos, monócitos e 
granulócitos, surgindo como a condição ideal a ser testada nas experiências seguintes. Em 
seguida, procedemos ao recrutamento de doentes com AR crónica (n=5) e controlos saudáveis 
(n=10) e estudámos o efeito do celastrol em leucócitos periféricos, testando as condições 
experimentais pré-optimizadas. 
O nosso trabalho demonstrou que o celastrol não teve efeito significativo nos níveis de 
células CD14+ (monócitos), CD66b+ (granulócitos), CD19+ (células B) e CD3+ (células T), 
tanto nos indíviduos saudáveis como nos doentes com AR crónica.  
Em relação aos monócitos, o celastrol mostrou ser capaz de diminuir (após estimulação 
com LPS) a frequência e a expressão de CD16 e CD115, e restaurar a expressão de HLA-
DR e a frequência e expressão de CD86 para níveis basais nas células CD14+ totais de 
controlos saudáveis. Além disso, nos doentes com AR crónica, celastrol foi capaz de 
reduzir a frequência de CD115 e diminuir (após estimulação com LPS) a frequência de 
CD86 nas células CD14+ totais. 
No que diz respeito aos granulócitos, o celastrol foi capaz de reduzir a expressão de 
CD62L e restaurar a expressão de CD11b e a frequência de CXCR2 para níveis basais nas 
células CD66b+ totais de controlos saudáveis. Nos doentes com AR crónica, o celastrol foi 
capaz de restaurar a expressão de CD11b para níveis basais nas células CD66b+ totais. 
Quanto às células T, o celastrol foi capaz de aumentar a frequência de células central 
memory Th2-like (CXCR3-CCR6-) e effector memory Th2-like (CXCR3-CCR6-) e 
restaurar a frequência das naïve activated T helper (CD45RO-HLA-DR+) para níveis basais 
de controlos saudáveis. Nos doentes com AR crónica, o celastrol foi capaz de aumentar a 
frequência de células memory activated T helper (CD45RO+HLA-DR+). Para além disso, o 
celastrol foi capaz de reduzir (após estimulação com LPS) a expressão de CXCR3 para 
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níveis basais nas células CD3+ totais e nas T helper (CD3+CD4+) de controlos saudáveis. 
No que concerne às células B, o celastrol foi capaz de diminuir a frequência de RANKL 
e CD95 nas células transitional (IgD+CD38++) e a expressão de CD95 nas naïve 
(IgD+CD27-) e transitional (IgD+CD38++) de controlos saudáveis. Além disso, o celastrol 
foi capaz de restaurar a frequência de RANKL para níveis basais nas células CD19+ totais, 
nas naïve (IgD+CD27-), pre-switch memory (IgD+CD27+) e post-switch memory (IgD-
CD27+) de controlos saudáveis. Nos doentes com AR crónica, o celastrol foi capaz de 
restaurar a frequência e expressão de CD95 e a expressão de FcgRIIB para níveis basais nos 
plasmablasts (IgD-CD38++); restaurar a frequência de CD95 e a expressão de CD21 para 
níveis basais nas células naïve (IgD+CD27-) e a expressão de CD21 para níveis basais nas 
células CD19+ totais; e restaurar (após estimulação com LPS) a frequência de HLA-DR 
para níveis basais nas células transitional (IgD+CD38++). 
Celastrol parece ter um efeito mais forte sobre as células do sistema imune inato, 
reduzindo a sua activação geral, diferenciação e potencial de migração. Desta forma, 
celastrol é um candidato promissor para futuros ensaios clínicos em doentes com AR. Além 
disso, estes resultados sugerem que o celastrol também pode ser benéfico para o tratamento 
de algumas outras doenças autoimunes além da artrite. 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: Artrite reumatóide; celastrol; leucócitos; inflamação; dano ósseo. 
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CHAPTER I –  
 
1. RHEUMATOID ARTHRITIS (RA) 
 
1.1. DEFINITION 
 
 
Rheumatoid arthritis (RA) is a progressive immune-mediated inflammatory disease 
characterized by chronic synovial inflammation, bone erosion and cartilage destruction in 
the joints. If not properly treated, RA leads to deformities, functional disability and 
reduced life expectancy (Wolfe FE and Hawley DJ, 1998; Pincus TE et al., 1994).  
The most common symptoms of RA include symmetrical inflammation of small joints 
(hands and feet) and latter of larger joints (shoulders, elbows, hips, knees and ankles), 
accompanied by swelling, pain, morning stiffness and fatigue. This disease is often 
associated with other comorbidities, such as cardiovascular, pulmonary, psychological and 
skeletal disorders (Kourilovitch M et al., 2014; Michaud K et al., 2007).  
The RA incidence is higher in individuals between 30 to 50 years of age, affecting 
more frequently women (≈75%), and is a relatively frequent disease with an overall world 
prevalence of 0,5% - 1% (Alamanos Y et al., 2005). In Portugal, RA affects about 0,7% of 
the population (Branco JC et al., 2016), which represents a significant impact on health 
systems (Laires PA et al., 2016). 
Currently, RA diagnosis is performed according to the 2010 American College of 
Rheumatology/European League Against Rheumatism (2010 ACR/EULAR) criteria which 
focus on some patient parameters including: the clinical history of the patient; the joint 
involvement (the number of swollen or tender joint); the presence of autoantibodies in the 
serum, such as rheumatoid factor (RF) and/or anti-citrullinated protein antibody (ACPA); 
the raised levels of inflammatory markers in the blood such as C-reactive protein (CRP) 
and erythrocyte sedimentation rate (ESR); the radiologic analyses and symptoms duration 
(Aletaha D et al., 2010). It is important to diagnose RA in the earliest possible phase of the 
disease course, since a prompt diagnosis and an accurate early therapeutic strategy are 
essential to prevent disease progression and joint erosions (Emery P et al., 1997). 
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1.2. ETIOLOGY 
 
 
RA is a disease of unclear etiology, however, various factors including genetic and 
environmental factors are thought to promote RA development (Davidson A et al., 2001).  
RA develops in a genetically susceptible host and some of the alleles associated with 
RA have been described. Human Leukocyte Antigen (HLA) emerge as the most important 
genetic factor for the susceptibility of this disease (Huizinga TW et al., 2005). HLA gene 
complex encodes the major histocompatibility complex (MHC) proteins, which are cell-
surface proteins responsible for the immune regulation, by presenting foreign molecules 
(antigens) to T cells, leading to T cell activation.  
HLA-DRB1 risk alleles are the most significant genetic susceptibility locus in RA, and 
genetic studies have shown that RA in the Caucasian population is strongly linked to the 
HLA-DRB1*01, HLA-DRB1*04 and HLA-DRB1*10 alleles (Raychaudhuri S et al., 2012). 
Moreover, regarding the environmental risk factors, several studies have reported that 
smoking is the most important risk factor for RA in individuals with HLA-DRB1 
susceptibility alleles (Symmons DP et al., 1997), promoting the development of 
autoantibodies, RFs or ACPAs (Morgan AW et al., 2009; Klareskog L et al., 2006), which 
are predictor factors for a severe form of RA. The female gender, older age, lifestyle, diet, 
obesity and infectious agents amongst others, are also associated with an increased risk for 
developing RA (Gerlag DM et al., 2016; Alamanos Y et al., 2005). 
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1.3. PATHOPHYSIOLOGY 
 
 
RA is characterized by leukocyte recruitment from the peripheral blood circulation into 
the synovial fluid and synovial tissue. This pathology involves a complex network of 
immune cells: macrophages and neutrophils from the innate immune system, and 
lymphocytes (T and B cells) from the adaptive immune system. These cells infiltrate the 
synovial membrane and secrete pro-inflammatory cytokines, particularly interleukins (IL)-
1β, IL-6 and IL-17 and tumor necrosis factor (TNF), as well as the excess of other 
inflammatory mediators, including chemokines and soluble adhesion molecules (Mclnnes IB 
et al., 2007). Before these events take place, neutrophils migrate to the synovial fluid, where 
they phagocyte immune complexes and release powerful proteases (Nathan C, 2006). The 
RA synovial tissue is highly infiltrated with macrophages and lymphocytes (T and B cells) 
while the synovial fluid has large numbers of neutrophils (Harris ED., 1994) (Figure 1). 
 
 
 
 
Figure 1 – Representation illustrating and comparing healthy (Normal joint) and arthritic (RA joint) articular 
joint. The RA joint shows increased inflammation and cellular activity (Smolen JS et al., 2016). 
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Aside from the synovial inflammatory cellular infiltration, the synovial tissue lining, 
composed of a thin layer of synoviocytes (macrophage-like and fibroblast-like synoviocytes 
(FLSs)), undergoes hyperplasic and expands, leading to a persistent inflammation associated 
with articular cartilage (Muller-Ladner U et al., 1996) and bone damage (Tolboom TCA et 
al., 2005).   
 
Figure 2 – Schematic representation of the inflammatory microenvironment in inflamed joints and events occurring 
in Rheumatoid Arthritis. The interactions among antigen-presenting cells (APCs), T cells and B cells would activate 
immune response, leading to the production of autoantibodies and excessive T cell activation. Subsequently, these T 
cells would continuously activate monocytes, macrophages and synovial fibroblasts, with up-regulated inflammatory 
cytokines, chemokines and matrix metalloproteinases (MMPs). Macrophages might differentiate into osteoclasts, 
which would resorb and destroy bone. Blys – B lymphocyte stimulator. C’ – complement. CP – citrullinated peptide. 
CR – complement receptor. FcR – receptor for the Fc portion of IgG. IC – immune complex. IFN – interferon. IFN1 – 
type 1 interferons. IL – interleukin. RF – rheumatoid factor. TACI – transmembrane activator and calcium-modulator 
and cyclophilin ligand interactor. TCR – T-cell receptor. Th1 – T-helper 1 cell. TLR – Toll-like receptor. Treg – 
regulatory T cell (Smolen JS et al., 2016). 
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The synovial hyperplasia phenomenon is named of the synovitis and is not only caused 
by the homing of these cells into the synovia, but also by the perpetuation of the 
inflammatory process due to the production of cytokines that maintain inflammatory cells 
activated (Harris ED et al., 1990) (Figure 2). 
RA was classically considered mainly as a T-cell driven disease. Invading T cells are 
activated when it occurs the T-cell receptors (TCRs) interaction and signaling via 
costimulatory molecules, including Cluster of Differentiation (CD) 28 (on the T cells) 
binding to CD80/CD86 (on the APCs), which are essential for the initial T cell activation, 
leading to an upregulation of CD40L (Frauwirth KA et al., 2002; Janeway CAJ et al., 1994; 
Lenschow DJ et al., 1996). Then, T cells activated will lead to the activation of synovial 
monocytes, macrophages and synovial fibroblasts, through the production of interferon-
gamma (IFN-γ) (Lundy SK et al., 2007; Kinne RW et al., 2007). CD40L interaction with 
CD40 on the APCs, also leads to activation of synovial monocytes/macrophages, 
fibroblast-like synoviocytes (FLS), and B cells, and may play a critical role in repeated 
activation of memory T cells in the synovium and, thus, maintenance of inflammatory 
reactions (Howland KC et al., 2000).  
The subsequent overproduction of IL-1β (Ruscitti P et al., 2015; Wei S et al., 2005; 
Jules J et al., 2012), IL-6 (Axmann R et al., 2009; Yoshida Y et al., 2014), IL-17 (Lubberts 
E et al., 2005; Jovanovic DV et al., 1998; Yago T et al., 2009) and TNF (Azuma Y et al., 
2000; Kanazawa K et al., 2005; Zhang YH et al., 2001) will induce monocytes/macrophages 
(osteoclast precursors) to express the receptor activator of nuclear factor (NF)-kB (RANK), 
which after binding to its ligand (RANKL) secreted by osteoblasts, stimulate their 
differentiation into mature osteoclasts that are responsible for bone resorption (Figure 3) 
(Pettit AR et al., 2001; Redlich K et al., 2002; Boyce BF et al., 2008). Differentiation of 
osteoclasts from their mononuclear precursors also requires macrophage-colony stimulating 
factor (M-CSF), engaging its receptor CD115 (c-Fms) on the surface of 
monocyte/macrophage precursors. Both RANKL and M-CSF are abundant in the 
synovium, providing the prerequisite milieu for osteoclastogenesis (osteoclast formation 
and maturation process) (Firestein G et al., 1988; Gravallese EM et al., 2000; Shigeyama Y 
et al., 2000). 
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Physiological bone resorption is typically followed by formation through osteoblasts, 
permitting the essential replacement of old skeletal tissue with new. This relationship 
between osteoclast and osteoblast function is disrupted in RA, which is characterized by 
limited bone formation despite high resorptive activity. Thus, in the RA pathogenesis there 
is an imbalance between pro- and anti-inflammatory mediators and of bone resorption and 
formation due to the predominance of the pro-inflammatory signals and bone resorption. 
In RA the mechanisms of neutrophil activation, recruitment and apoptosis are altered. 
Circulating neutrophils from RA patients seem to have decreased levels of spontaneous 
apoptosis (Weinmann P et al., 2007). Herein, there is an impairment of neutrophil clearance 
and the ingestion of these cellular by macrophages induces production of pro-inflammatory 
cytokines, thus amplifying the inflammatory scenario (Sweeney SE, Firestein GS, 2004). 
Activated neutrophils specifically play an important role in the onset and perpetuation 
of RA, not only as pro-inflammatory cytokine (such as IL-1β and TNF) and chemokines-
producing cells, but also for being responsible for the release of high amounts of reactive 
oxygen species (ROS) and destructive enzymes, such as metalloproteinases (MMPs), 
contributing to inflammation and joint erosions (Nathan C et al., 2006; Scapini P et al., 
2000; Cascao R et al., 2010). 
B cells contribute to RA pathogenesis not only through antigen presentation, but also 
through the production of antibodies, autoantibodies and cytokines (Smolen JS et al., 2007). 
B cells, once differentiated as plasma cells, are able to produce and release autoantibodies 
such as Rheumatoid factor (RF) and Anti-citrullinated protein antibodies (ACPA), which 
can occur even before the clinically onset of disease (Edwards CJ et al., 2006).  
These autoantibodies can form larger immune complexes which can activate 
Figure 3 – RANK/RANKL signaling pathway representation and osteoclastogenesis. Osteoblasts in bone produce 
receptor activator of nuclear factor kappa-B ligand (RANKL). RANKL activates its receptor, RANK, which is expressed 
on the surface of pre-fusion osteoclasts, generating activated osteoclasts (Josse RG, 2009). 
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inflammatory cells (macrophages), and further stimulate the production and release of 
several pro-inflammatory cytokines (including TNF, IL-1β and IL-6) in synovial tissue 
(Kinne RW et al., 2007), that exacerbate the inflammatory process as previously described 
(Smolen JS et al., 2007). Interestingly, it has been evidenced that a decreased B cell count, 
corresponding to lower memory B cell numbers, in the periphery, is associated with 
arthritis development (Lubbers J et al., 2015). 
Recent evidences have indicated clear involvement of Th17 and regulatory T (Treg) 
cells in the RA pathogenesis (Alzabin S et al., 2011; Wehrens EJ et al., 2013), and a 
relatively small contribution of Th1 in the global context of this disease (Boissier MC et al., 
1995). Of note, Th2 cells seem to only have a modest contribution for RA pathogenesis as 
can be appreciated by the low expression level of their cytokines in the synovial tissue 
(Woods JM et al., 1997; Morita Y et al., 1998). 
Previous studies have implicated IL-17-producing T cells (Th17) as important effectors 
in RA pathogenesis due to the overexpression of IL-17 in the synovial fluid, which is 
associated with an aggravation of inflammation and joint damage (Lubberts E et al., 2005; 
Chabaud M et al., 1999). Concretely, this cytokine is involved in overexpression of other 
cytokines, cartilage-destructive enzymes and also expression of bone destruction-related 
mediators, such as RANKL (Mclnnes IB et al., 2007; Choy EH et al., 2001). In fact, the 
percentage of Th17 cells is increased in RA synovial fluid in comparison with RA or normal 
peripheral blood (Shahrara S et al., 2008). Previous reports have demonstrated that IL-6 and 
IL-1β secreted by self-reactive T cell-stimulated APCs, are able to induce the differentiation 
of naïve self-reactive T cells into Th17 cells (Hirota K et al., 2007; Chung Y et al., 2009; 
Kryczek I et al., 2007), via ‘retinoic acid receptor-related orphan receptor gamma T’ 
(RORgT). In fact, cytokines that support Th17 differentiation, suppress Treg cells 
polarization, and consequently shift T cell homeostasis towards inflammation. 
Regulatory T (Treg) cells have been detected in the blood and in synovium of RA 
patients with active disease and particularly in synovial fluid, but they seem to have 
impaired regulatory function (Ehrenstein MR et al., 2004). Contrarily to Th1, Th2 and Th17 
cells, Treg cells are characterized by low proliferative capacity upon triggering the T cell 
receptor (TCR) and by their ability to suppress CD4+ and CD8+ T-cell immune responses 
(Suri-Payer E et al., 1998). Thus, to prevent overshooting T-cell activation, a means of T-
cell control is achieved by Treg cells, a population of CD4+CD25+ cells expressing the 
transcription factor ‘forkhead box protein 3’ (Foxp3) that effectively suppresses T-cell 
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activation. However, several studies have pointed out that Treg cells are deficient in RA 
(Ehrenstein MR et al., 2004) suggesting that in fact a breakdown of Treg-mediated 
peripheral tolerance may have occurred (Suri-Payer E et al., 1998; van Amelsfort JM et al., 
2004; Moradi B et al., 2014). 
Accordingly, an imbalance between the T regulatory cells (Treg) and the T helper cells 
(Th17) in RA patients has been reported and associated with the disease development (Niu 
Q et al., 2012).  
 
 
1.4. TREATMENT OPTIONS 
 
 
The treatment goal in RA is remission (van Tuyl LH et al., 2009; van Tuyl LH et al, 
2010) which is achieved in 20%-30% of patients if early and optimally treated (Lindqvist E 
et al., 2002). 
In the last decades, there was a great improvement in RA therapeutic approaches, 
however despite all available treatment options, RA remains an incurable, progressive and 
debilitating disease (Burmester GR et al., 2017). Glucocorticoids (GCs), conventional and 
targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) and biologic 
DMARDs, represent the most commonly used therapeutic strategies in the treatment of RA 
(van Vollenhoven RF et al., 2009; Yang M, et al., 2017). 
GCs such as prednisolone and dexamethasone are suppressors of the inflammatory 
response and, consequently of the pain and swelling (Gaffo A et al., 2006), reducing 
synovitis in the short-term and decreasing joint damage in the long-term (Kirwan JR et al., 
2007). GCs are widely used in treating active RA but side effects such as 
immunosuppression, osteoporosis, hyperglycaemia and hypertension associated with the 
dosage cannot be ignored during long-term therapy (Polido-Pereira J et al., 2011; van 
Vollenhoven RF et al., 2009). Currently, GCs are used in an initial phase of the disease and 
are useful to control symptoms immediately after diagnosis, until slower-action DMARDs 
can start to have an effect (Smolen JS et al., 2017).         
Conventional synthetic DMARDs (csDMARDs) such as methotrexate (MTX), 
hydroxychloroquine, sulfasalazine and leflunomide are the most used drugs to efficiently 
treat RA patients (Donahue KE et al., 2008). csDMARDs can slowly (1 up to 6 months) 
relieve joint damage and control the disease progression, reducing synovitis and systemic 
9 
 
inflammation and improving function (Gaffo A et al., 2006; Cronstein B et al., 2005). MTX 
is the most commonly used csDMARD agent, and it is effective on standard clinical 
measures of disease activity (Strand V et al., 1999) cost-effective and comparatively well 
tolerated. csDMARDs have been shown to provide a more favourable outcome in patients. 
However, approximately 30% of the patients are either non-responsive to csDMARDs or 
lose response over time or experience adverse events following treatment (Cash JM et al., 
1994; Nagashima M et  al., 2006; Keystone EC et al., 1999; Rau R, 2010). 
Biologic DMARD agents (bDMARDs) have been developed to target a specific 
molecule and/or pathway and are used when arthritis is uncontrolled or toxic effects arise 
with csDMARDs. Among them, inhibition of TNF, IL-1β, IL-6 receptor, T-cell 
costimulation blockade, and B-cell depletion have appeared as an alternative to 
csDMARDs (Nam JL et al., 2017). Evidences suggest that biologic agents are highly 
effective, although 30% of patients still show low efficacy. In addition, various problems 
are associated with current biological therapies, since they must be administered 
parenterally, have adverse events and high costs, as they are considerably more expensive 
than standard treatment options (Koenders MI et al., 2015; van Vollenhoven RF et al., 
2009). 
Lastly, targeted synthetic DMARDs (tsDMARDs) which are also developed to target a 
specific molecule/pathway, but unlike the biologics these are small molecules. Tofacitinib 
and baricitinib are two examples of small-molecule Janus kinase (JAK) inhibitors (Smolen 
JS et al., 2016; Nam JL et al., 2017). tsDMARDs are recommended only after failure to 
meet the treatment goal with MTX (Smolen JS et al., 2017) or more than one bDMARD.   
Unfortunately, the most recent and innovate therapies are highly expensive limiting the 
access to the standard of care. Moreover, many of these therapies are only effective in 
controlling inflammation or protecting bone damage (Fonseca JE et al., 2009; Joosten LA et 
al., 1999), which is the major burden in RA patients. Consequently, the development of less 
expensive small molecules for the treatment of RA which are safe and effective in the 
control of both inflammation and bone damage, is still a medical unmet need. 
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2. CELASTROL 
 
2.1. CELASTROL 
 
 
The growing need for safe therapies led to the discovery of a Chinese herb, the 
Tripterygium wilfordii, which has been used for centuries in the chinese medicine to treat 
inflammation and autoimmune related diseases including RA (Sassa H et al., 1990; Allison 
AC et al., 2001; Kim DH et al., 2009; Jaquet V et al., 2011; Venkatesha SH et al., 2011; 
Brinker AM et al., 2007; Lipsky PE and Tao XL, 1997; Qiu D and Kao PN, 2003; Canter 
PH et al., 2006). Extracts from Tripterygium wilfordii have already been used in RA 
patients (Tao X et al., 2002; Goldbach-Mansky R et al., 2009; Jiao J et al., 2012; Cibere J et 
al., 2003; Lv QW et al., 2015; Wu YJ et al., 2001; He WZ et al., 2014), reducing disease 
activity as effectively as csDMARDs (Liu Y et al., 2013; Wang HL et al., 2016). However, 
despite its potencial clinical usefulness, contradictory data regarding efficacy and safety has 
been published (Canter PH et al., 2006; Cameron M et al., 2011; Jiang Q et al., 2009; Qian 
SZ et al., 1987; Matlin SA et al., 1993; Yuan YY et al., 1995). Of note, herbal extracts 
exhibit a high variability in the concentration/quality of their bioactive constituents and the 
products used for extraction methods might cause tolerability problems, thus, the use of a 
purified component isolated from Tripterygium wilfordii that possesses the disease-
modulating attribute of the natural plant extract may circumvent these limitations 
(Venkatesha SH et al., 2011). 
Celastrol, is a bioactive of Tripterygium wilfordii that has already shown to possess 
potent anti-inflammatory, anti-tumoral and neuroprotective properties in in vitro and in 
animals models of cancer (Yu X et al., 2015; Li H et al., 2010; Zhao F et al., 2010; Zhou GS 
et al., 2011a; Abbas S et al., 2007; Lee JH et al., 2006; Davenport A et al., 2010), 
inflammatory (Ding Q et al., 2013; Kim DY et al., 2009; Kim DH et al., 2009; Shaker ME et 
al., 2014; Pinna GF et al., 2004) and neurodegenerative diseases (Paris D et al., 2010; Choi 
BS et al., 2014). These significant therapeutic properties of celastrol support the growing 
interest on treating patients with celastrol. 
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2.2. CELASTROL IN ARTHRITIS 
 
 
The anti-inflammatory properties of celastrol can be mainly attributed to the regulation 
of cytokine and chemokine production (Kim DH et al., 2009; Lee JH et al., 2006; 
Venkatesha SH et al., 2011; Venkatesha SH et al., 2012; Lee JY et al., 2015; Cascão R et 
al., 2012; Cascão R et al., 2015), the modulation of inflammatory cell functions (Li G, Liu 
D et al, 2013; Li G et al., 2012; Li G et al., 2013; Yu Y et al., 2015; Astry B et al., 2015; 
Cascão R et al., 2015), osteoclast modulation and bone damage control (Idris AI et al., 
2010; Nanjundaiah SM et al., 2012; Gan K et al., 2015; Cascão R et al., 2015), mostly due 
to its ability to downregulate the NF-kB pathway. 
Using an adjuvant-induced rat model of arthritis (AIA), several studies have reported 
the anti-inflammatory and bone protective effects of celastrol via the inhibition of pro-
inflammatory cytokines (such as TNF, IL-1β (Venkatesha SH et al., 2012; Cascão R et al., 
2012; Li H et al., 2008; Astry B et al., 2015), IL-17, IL-6 and IL-8 (Nanjundaiah SM et al., 
2012; Venkatesha SH et al., 2011)) and the levels of chemokines (such as the ‘regulated 
upon activation, normally T cell expressed and secreted’ (RANTES) and monocyte 
chemotactic protein 1 (MCP-1)) that mediate cellular infiltration into the joints (Venkatesha 
SH et al., 2012). Celastrol also reduces the number of Th17 cells and conversely, 
significantly increases Treg cells in the synovial tissue, promoting a restore of Th17/Treg 
balance (Astry B et al., 2015). Moreover, a significant inhibitory effect on antibody 
response by reducing serum levels of ACPA antibodies of the IgG class has also been 
observed in the same rat model upon celastrol adiminstration (Venkatesha SH et al., 2011). 
Using the same model of arthritis (AIA) celastrol has also shown a significant inhibitory effect 
on inflammatory arthritis and on the reduction of bone and cartilage damage by suppressing 
mediators of osteoclastic bone remodeling, RANKL expression and osteoclast numbers 
(Nanjundaiah SM et al., 2012). Also, celastrol can protect chondrocytes by downregulating 
the expression of metalloproteinases, inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) protein (Ding Q et al., 2013). 
Other studies using celastrol have also reported beneficial effects in various models of 
inflammation, in addition to AIA, such as in the collagen-induced arthritis (CIA) model, 
where it has also been observed that celastrol suppresses arthritis and bone damage as it is 
able directly inhibit osteoclast differentiation/formation (osteoclastogenesis) and function 
and consequently prevent bone destruction (Gan K et al., 2015; Nanjundaiah SM et al., 
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2012). It has been shown in the joints of CIA mice and in RAW264.7 macrophagic murine 
cell line, that celastrol inhibits the formation of the osteoclasts cells and reduces the 
expression of osteoclastic genes and transcriptional factors beyond the bone-resorbing 
activity (Gan K et al., 2015). 
It has also been described in cells isolated from RA patients and cultured in vitro, that 
celastrol can normalize synovial features inhibiting human RA fibroblast-like synoviocytes 
(FLSs) proliferation (Xu Z et al., 2013) and their migration and invasion (Li G et al., 2012; 
Li G et al, 2013; Li G, Liu D et al, 2013), possibly through suppression of Fas receptor 
(FasR) (also known as CD95; involved in cell apoptosis) (Xu Z et al., 2013), MMP-9 
expression (responsible for bone and cartilage matrix degradation) (Li G et al., 2012; Li G 
et al, 2013), CXC chemokine receptor 4 ( CXCR4) (involved in invasion processes) and 
hypoxia-inducible factor-1α (HIF-1α) expression (regulator in the cellular response to hypoxic 
conditions) (Li G, Liu D et al, 2013), respectively. Additionaly, it has been shown that 
celastrol specifically impairs the development of B cells in peripheral blood (Kusy S et al., 
2012).  
Based on previous data from our group showing that IL-1β plays an important role 
since the early phase of RA (Cascão R, Polido-Pereira J et al., 2012; Cascão R et al., 2010) 
and that pathways regulating this cytokine, together with TNF, can constitute promising 
combined therapeutic targets for RA, we have performed an in vitro drug screening 
(Figueiredo et al., ?) for compounds that simultaneously inhibit IL-1β and TNF production 
(Cascão R et al., 2012) and have identified celastrol as a promising therapeutic candidate.  
Using the AIA rat model we have also demonstrated that this compound has significant 
anti-inflammatory and anti-proliferative properties through suppressing joint inflammation 
(ankle swelling, joint inflammatory cell infiltration and proliferation) (Cascão R et al., 
2012) as well as reducing synovial infiltration of CD3+ T cells, CD19+ B cells, CD163+ 
macrophages, and most importantly, CD68+ macrophages (a biomarker of drug efficacy in 
RA) (Cascão R et al., 2015). Importantly, we have also revealed that celastrol has bone 
protective effects in the AIA rat model, as it is able to decrease the number of osteoclasts 
and osteoblasts present in arthritic joints and reduce local bone erosions, systemic bone loss 
and microarchitecture degradation (Cascão R et al., 2017).  
Recently our own data showed in vivo in the same animal model, that the doses of 2,5 
and 5µg/g/day are effective and non-toxic in the treatment of arthritis. However, lower 
concentrations immediately lose efficacy and higher concentrations show signs of toxicity 
(our unpublished data). These results are crucial for future experiments in order to 
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determine the maximum safe dose and pharmacokinetics in healthy rats, and predict the 
first-in-human dose in future experiments. 
Altogether, these data showing that celastrol can effectively control the arthritis 
progression due to suppress not only the inflammation mediators but also to prevent 
cartilage damage and bone resorption, suggest that this compound constitute a promising 
candidate to the therapeutic targets of arthritis and subsequently, a new and suitable 
treatment option for RA disease. 
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CHAPTER II –  
 
 
Celastrol has shown inhibitory effects in inflammation as well as in cartilage and bone 
damage in vivo and in vitro. Thus, this compound can constitute a promising candidate in the 
treatment of RA. Based on previous data about celastrol effects and considering the unmet 
medical need in RA therapeutic options, we hypothesize that celastrol is able to restore bone 
and inflammatory markers to basal levels and counteract joint infiltrating immune cells in 
RA patients. Therefore, we find convenient and appropriate to investigate the effect of 
celastrol on several leukocyte cell populations such as monocytes, granulocytes and 
lymphocytes as well as their subsets, on peripheral blood samples collected from RA 
patients.  
The goal of this project is to analyze the effect of celastrol with or without LPS 
stimulation on primary human leukocytes (such as monocytes, granulocytes, T cells and 
B cells and their subsets) activation, maturation, survival and apoptosis using peripheral 
blood samples collected from RA patients in comparison with healthy controls. In order 
to accomplish this, after celastrol incubation, cell viability is assessed using alarmarBlue® 
by spectrophotometry assay, and an immunophenotyping characterization of monocytes, 
granulocytes, T and B cells is performed by Flow Cytometry. 
The present project is innovative because it enables a very complete understanding 
underlying the effect of celastrol on primary immune cells. 
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CHAPTER III –  
 
1. COMPOUNDS 
 
 
Celastrol was purchased from Sigma (Missouri, USA), dissolved in ethanol 100% as 
solvent (absolute ethanol) (Qi X et al., 2014) and stored as aliquots (stock solution of 10 
mg/mL) at –20oC until used. 
Purified lipopolysaccharide (LPS) from Escherichia coli was purchased from Sigma 
(Missouri, USA), dissolved in Phosphate Buffered Saline (PBS) 1x and stored as aliquots 
(1000 μg/mL) at -20oC until used. 
 
 
2. HUMAN SAMPLES   
 
 
Peripheral blood samples were collected from RA patients (n=5) (Rheumatology 
Department, Hospital de Santa Maria, Lisbon) with active disease (disease score > 3.2) and 
healthy individuals (n=10) used as controls (Table 1). Patients cohort included RA patients 
who fulfilled the 2010 ACR/EULAR criteria for RA (Aletaha D et al., 2010) with more than 
1 year of disease duration, RF and/or ACPA positivity (seropositive) and treated with 
methotrexate (MTX) ± prednisone (PDN) ≤ 7,5 mg/day ± NSAIDs. 
The disease activity score using 28 joint counts (DAS28) were applied to all patients. 
This study was approved by the local ethics committee (Comissão de Ética do Hospital de 
Santa Maria, Lisbon, Portugal) and all patients and healthy donors signed an informed 
consent form. Patient care was conducted in accordance with standard clinical practice and 
the study was performed in accordance with the Declaration of Helsinki as amended in 
Fortaleza, Brazil (2013). 
Blood was collected for tubes containing Sodium Heparin to proceed to the isolation of 
leukocytes. Additionally, blood were also collected for a vacutainer blood collection tube 
containing anticoagulant EDTA (BD Vacutainer®), to perform white blood cell (WBC) 
count using a pocH-100iV Diff ™ Automated Hematology Analyzer (Sysmex).  
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3. ISOLATION OF LEUKOCYTES FROM BLOOD 
 
 
Blood was resuspended and incubated in an erythrocyte lysis buffer (Red Blood Cell 
(RBC) lysis buffer) at 1:10 dilution, for 10 min at room temperature (RT). After 
centrifugation at 300g, for 15 min at RT, the supernatant was discarded and the white blood 
cells (WBC) fraction (pellet) was collected. Cells were resuspended in RPMI 1640 ( 
ThermoFisher Scientific) supplemented with 10% (v/v) Fetal Bovine Serum (FBS), 1% (v/v) 
Penicillin-Streptomycin (Pen-Strep), 1% (v/v) Sodium Pyruvate, 1% (v/v) L-Glutamine, 1% 
(v/v) MEM Non-essential aminoacids, 1% (v/v) HEPES Buffer and 0,05 mM 2-
mercaptoethanol (ThermoFisher Scientific). Viable peripheral WBCs were count using 
Trypan Blue dye (BioWhittaker™) on a Neubauer Chamber (hemocytometer).  
 
4. IN VITRO TEST OF CELASTROL 
 
4.1. OPTIMIZATION OF EXPERIMENTAL CONDITIONS  
   
 
 
Cells were seeded into 24-well plates at a density of 1x106 cells per well, incubated with 
a range of celastrol concentrations (0,001 µM, 0,01 µM, 0,05 µM, 0,1 µM, 0,3 µM, 0,5 µM 
and 1 µM) and stimulated with LPS (2 μg/mL, 5 μg/mL and 10 μg/mL), for different 
incubation times (0h, 4h, 16h and 24h) in a 5% CO2 enriched atmosphere at 37
oC and 
protected from light exposure. Four experimental conditions were studied: Media + Ethanol 
100% (solvent); Media + Ethanol 100% + LPS; Media + Ethanol 100% + Celastrol and 
Media + Ethanol 100% + Celastrol + LPS. The condition Media + Ethanol 100% was used 
as a control condition. Accordingly, one condition studied either at 0h incubation time as in 
the incubation time to be tested, in particular, Media (Media Only) was used as control 
condition. Cell viability was assessed using alamarBlue® cell viability test by 
spectrophotometry and 7-Amino-actinomycin D (7-AAD) Apoptosis Staining by Flow 
Cytometry, to subsequently determine the best compounds concentrations and incubation 
time to use. Triplicates of each experimental condition were used. 
The selection of the range of concentrations to be tested were based in in vitro 
experiments and in in vivo pharmacokinetics tests of celastrol reported by Zhang J et al. 
(Zhang J et al., 2012).  
17 
 
4.2. OPTIMIZED IN VITRO TEST OF CELASTROL 
 
 
Cells were seeded into 24-well plates at a density of 1x106 cells per well, incubated with 
0,3 µM of celastrol and stimulated with 10 μg/mL LPS for 4h in a 5% CO2 enriched 
atmosphere at 37oC and protected from light exposure. Four experimental conditions were 
used: Ethanol 100% (solvent) + Media; Celastrol 0,3 µM + Media; LPS 10 μg/mL + Media 
and Celastrol 0,3 µM + LPS 10 μg/mL + Media. Duplicates of each condition were used to 
evaluate cell viability using alamarBlue® cell viability test by spectrophotometry assay. The 
immunophenotyping characterization of WBC subpopulations, including monocytes, 
granulocytes, T and B lymphocytes from each condition was performed by Flow Cytometry. 
 
 
5. FLOW CYTOMETRY   
 
5.1. ANTIBODIES 
 
 
Antibody titration was performed using the concentration indicated in the respective 
data sheet (1:20 ratio) and two concentrations below (1:40 and 1:100 ratio) directly stained 
on 100 μL peripheral blood cells of healthy controls, in order to define the concentration that 
better stain and present well defined cell subsets with the brightest signal. 
Immunophenotyping characterization of monocytes, granulocytes, T and B cells and 
their subsets was performed in primary human leukocytes isolated from peripheral blood 
samples of healthy controls and chronic RA patients after incubation.  
For B cell analysis, combinations of anti-CD19 PerCP-Cy5.5, anti-IgD PE-Cy7, anti-
CD27 eFluor450, anti-CD38 APC-eFluor 780, anti-BAFF-R PE, anti-FcgRIIB (CD32) 
APC, anti-HLA-DR APC, anti-CD21 PE, anti-CD95 APC and anti-RANKL PE were used. 
T cells were studied with combinations of anti-CD3 APC, anti-CD4 PerCP-Cy5.5, anti-
CD8 PE, anti-CD45RO APC-eFluor 780, anti-CD40L PE-Cy7, anti-HLA-DR eFluor 450, 
anti-CD25 PE-Cy7, anti-Foxp3 eFluor 450, anti-RORgT PE, anti-CCR6 PE, anti-CXCR3 
PE-Cy7 and anti-CCR7 Pacific Blue. 
For monocyte analysis, combinations of anti-CD14 PerCP-Cy5.5, anti-CD3 APC, anti-
CD86 PE, anti-HLA-DR eFluor 450, anti-CD16 APC-Cy7, anti-CD115 PE-Cy7 and anti-
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RANK PE were used. 
For granulocyte analysis, combinations of anti-CD66b PE-Cy7, anti-CD11b PerCP-
Cy5.5, anti-CD16 APC-Cy7, anti-CXCR2 PE, anti-CD62-L APC and anti-CD15 eFluor 450 
were used. 
Antibodies were purchase from eBioscience (USA), BD Pharmigen (USA), R&D 
Systems (United Kingdom), BioLegend (San Diego), Santa Cruz Biotechnology.  
 
 
5.2. LEUKOCYTE STAINING – PREPARATION OF SAMPLES TO FLOW 
CYTOMETRY 
 
 
After incubation with celastrol and LPS, cells were carefully ressuspended and 
transferred from the 24-well plates into to the cytometer tubes. After a centrifugation at 300g 
for 5 min at RT, supernatants from each tested condition were collected and stored at -80oC 
for future enzyme linked immunosorbent assay (ELISA) quantifications. Then, cells were 
washed with PBS1x and afterwards, they were resuspended in PBS1x for antibody staining 
for flow cytometry.  
 
5.2.1.  Cell surface staining protocol 
 
 
Cells were stained on ice for 15 minutes, with 9 different mixes of surface antibodies 
(Appendix I). Of note, the FVD FITC antibody was added to each Mix immediately prior to 
staining cells, to prevent any loss of staining intensity of the dead cells. After cell surface 
staining, cells were washed with PBS1x, ressuspended and centrifuged at 300g for 5 min at 
RT and protected from light exposure. The supernatant was discarded and then cells were 
ressuspended in 300 μL of PBS1x and stored at 4oC protected from light exposure until 
analyzed by flow cytometry. Samples were analyzed using a BD LSRFortessaTM Cell 
Analyzer (BD Biosciences, New Jersey, USA) with BD FACSDiva™ v6.1 Software (BD 
Biosciences, San Jose, CA). The data collected were further analyzed using FlowJo 9.8.2 
Software (Tree Star, Stanford University, USA).  
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5.2.2. Intracellular staining protocol 
 
 
Cells (corresponding to Mix 5) were ressuspended in PBS1x (100 μL) and then, the 
intracellular staining protocol was performed as described in the “Staining Intracellular 
Antigens for Flow Cytometry” protocol (eBioscience, USA). Briefly, cells were fixed during 
30 minutes on ice at 4oC with Foxp3 Fixation/Permeabilization working solution, 
permeabilized with 1x Permeabilization Buffer and stained with the intracellular antibodies 
(Foxp3 and RORgT), for 30 minutes on ice at 4oC in the dark. Finally, cells were washed 
twice with PBS1x, ressuspended and centrifuged at 300g for 5 min at RT, protected from 
light exposure. The supernatant was discarded and then, cells were prepared as samples to 
flow cytometry analysis. They were ressuspended in 300 μL of PBS1x and stored at 4oC 
protected from light exposure until analyzed by flow cytometry, as above mentioned. 
 
 
 
6. ALAMARBLUE® CELL VIABILITY ASSAY 
 
 
After the incubation with celastrol and LPS, cell viability was assessed by alamarBlue® 
assay (ThermoFisher Scientific) in accordance with the manufacturer’s instructions.   
Briefly, 10 % (v/v) of alamarBlue® reagent (resazurin) (100 μL) was added directly to the 
cells of each condition and incubated for 2 hours at 37oC and 5% CO2 in the dark. 
Fluorescence intensity was recorded with 570 nm excitation and 610 nm emission 
wavelengths, using a microplate reader Infinite M200 (Tecan, Switzerland). 
In the assessment of cell viability for optimization of the celastrol and LPS doses and 
durantion of incubation, the percentage/number of viable cells was determined by 
comparing each fluorescence value with the fluorescence obtained at the incubation time of 
0 h. For the remaining measurements, cell viability was determined by comparing 
fluorescence values with those corresponding to the media (control). 
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7. 7-AMINO-ACTINOMYCIN D (7-AAD) APOPTOSIS STAINING 
 
 
Cell death was determined by 7-Amino-actinomycin D (7-AAD) Apoptosis Staining 
(ThermoFisher Scientific), according to the provider’s instructions. The proportions of cells 
in either population undergoing apoptosis were detected by staining of apoptotic cells with 
7-AAD. After the incubation time of WBCs in the optimization of experimental conditions, 
5 μl of the ready-to-use reagent was added directly to cells of each condition and incubated 
for 5 minutes, to determine the best compounds concentrations and incubation time to use. 
Samples were then acquired with a BD AccuriTM Flow Cytometer (BD Biosciences). The 
data collected were further analyzed using FlowJo 9.8.2 Software (Tree Star, Stanford 
University, USA). 
 
 
8. STATISTICAL ANALYSIS  
 
 
The normality distribution was assessed by D’Agostino and Pearson omnibus normality 
test. For populations that did not follow a Gaussian distribution, the non-parametric Mann-
Whitney and Wilcoxon’s matched pairs signed rank tests were used. The Mann-Whitney test 
was used for comparisons between 2 independent groups and the Wilcoxon matched pairs 
test for comparisons between 2 paired groups. Statistical differences were determined with 
GraphPad Prism 6 Software (GraphPad, California, USA). Data are expressed as median 
with interquartile range. Differences were considered statistically significant for p-values < 
0,05. 
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CHAPTER IV –  
 
1. IN VITRO TEST OF CELASTROL  
 
1.1. OPTIMIZATION OF EXPERIMENTAL CONDITIONS 
 
 
We first proceeded to the optimization of experimental conditions. To this purpose, a 
group of healthy controls (n=4) was required to collect peripheral blood samples. Isolation 
of primary human leukocytes was performed and cells were incubated for 0h, 4h, 16h and 
24h with a range of concentrations of celastrol (0,001 µM, 0,01 µM, 0,05 µM, 0,1 µM, 0,3 
µM, 0,5 µM and 1 µM) and LPS (2 μg/mL, 5 μg/mL and 10 μg/mL). We assumed 100% of 
viability at 0h (control condition at baseline) and that cell viability reductions above 20% 
would be significant. 
   
 
1.1.1. INCUBATION TIME OPTIMIZATION OF CELASTROL 
 
Data from cell viability assay (Figure 4, showed the celastrol incubation during 24h 
was the incubation time which most affected the cell viability, specifically under the 0,3 µM, 
0,5 µM and 1 µM concentrations of celastrol (Figure 4C) when comparing to the control 
condition baseline at 0h (Media Only at 0h). However, not exceeding the value that we 
defined as the cutoff (20% decrease in cell viability), nor being decreased relative to the cell 
viability of the control conditions at 24h (Media Only at 24h and Media + Ethanol at 24h). 
Of note, comparing cell viability under these celastrol concentrations (0,3 µM, 0,5 µM and 1 
µM) to the cell viability baseline at 0h (control condition at 0h - Media Only at 0h), we 
noticed that celastrol already appears to slightly decrease cell viability after 24h of the 
incubation time, but still, with no marked toxicity (Figure 4C and 4D). Regarding to the 
incubation time at 4h and 16h, it was not observed a decrease in the cell viability in all 
celastrol concentrations when comparing to cell viability of control conditions at 0h and 
4h/16h, respectively (Media Only at 0h; Media Only at 4h/16h and Media + Ethanol at 
4h/16h) (Figure 4A, 4B and 4D).  
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AlamarBlue ® viability assay – Cell viability analysis  
 
Flow cytometry analysis showed that both at 16h and 24h of incubation with celastrol 
led to a significantly decrease of monocytes viability, in all tested concentrations, comparing 
to the control condition baseline at 0h (Media Only at 0h) (Figure 5v and 5vi). Moreover, 
lymphocytes viability also appeared to be affected either after 16h and 24h of incubation 
with celastrol (Figure 5ii). Contrarily, granulocytes viability was not impaired after 16h and 
24h of incubation with celastrol, when comparing to the control condition baseline at 0h 
(Media Only at 0h) (Figure 5viii and 5ix).  
These data lead us to exclud the 16h and 24h of incubation from our experimental set-
up and to select the incubation time of 4h.  
 
 
Figure 4 – Incubation time optimization of celastrol in in vitro. Cell viability analysis by alarmarBlue® assay. (A) Cell viability is not affected with 
a range concentrations of celastrol (0,001 µM - 1 µM) following 4h of incubation time. Healthy controls, n=4. (B) Cell viability is not affected with 
a range concentrations of celastrol (0,001 µM - 1 µM) following 16h of incubation time. Healthy controls, n=2. Instead, cell viability is increased 
after incubation of celastrol at both 4h (A) and 16h (B) incubation time. (C) Cell viability is not affected with a range concentrations of celastrol 
(0,001 µM - 1 µM) following 24h of incubation time. Healthy controls, n=2. However, slightly decrease of cell viability after 24h incubation time, 
when comparing to 4h and 16h, was observed, but sill, not exceeding the value that we defined as the cutoff (80%). (D) Incubation times tested 
(4h, 16h and 24h) do not seem affect cell viability when incubated with a varying concentrations of celastrol (0,001 µM - 1 µM), and therefore, 
not appearing to represent apparent toxicity. Data from the alarmarBlue® cell viability assay. Data are expressed as mean with standard 
deviation. 
A B C 
D 
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Flow Cytometry – Cell viability and subpopulation percentage analysis 
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Figure 5 – Incubation time optimization of celastrol in in vitro. Cell viability and subpopulation percentage analysis by Flow Cytometry. 
Data from the Flow Cytometry analysis. Data are expressed as mean with standard deviation. 
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1.1.2. CONCENTRATION OPTIMIZATION OF CELASTROL 
 
After 4h of incubation with celastrol, we particularly found that the 0,1 µM and 0,5 µM 
concentrations of celastrol slightly reduced the monocytes viability, although, a more 
pronounced reduction was observed using the highest dose of celastrol (1 µM), when 
comparing to the control condition baseline at 0h (Media Only at 0h) (Figure 5iv). In 
addition, lymphocytes viability at 4h was essentially affected with 0,5 µM and 1 µM 
concentrations of celastrol, when comparing to the control condition baseline at 0h (Media 
Only at 0h), but with no evidence of significant reduction in viability (Figure 5i). 
Granulocytes viability appeared increased following 4h of incubation with celastrol (0,001 
µM - 1 µM), when comparing to the control condition baseline at 0h (Media Only at 0h) 
(Figure 5vii). As noted, the highest concentration of celastrol appears with apparent toxicity 
on monocytes and lymphocytes after 4h of incubation.  
In order to evaluate and select the best celastrol concentration (0,001 µM, 0,01 µM, 
0,05 µM, 0,1 µM, 0,3 µM, 0,5 µM or 1 µM) after 4h of incubation with this compound, a 7-
AAD Apoptosis Staining was performed by Flow Cytometry to analyze the cell death in the 
different subpopulations (Figure 6). 
 
 
Flow Cytometry – Cell viability and subpopulation percentage analysis 
7-AAD Apoptosis Staining – Subpopulations cell death analysis 
 
Figure 6 – Concentration optimization of celastrol in in vitro under incubation time of 4h. Analysis of subpopulations cell death by 7-
AAD Apoptosis Staining and Flow Cytometry. Data from the Flow Cytometry analysis. Data are expressed as mean with standard 
deviation. 
A B C 
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We observed that the highest dose of celastrol (1 µM) increased cell death in the 
lymphocytic population (Figure 6A). Concerning to the granulocytes, we observed that cell 
death was more pronounced at the highest dose of celastrol (Figure 6C). Concordantly, the 
highest concentration of celastrol also showed a marked increase in monocyte’s cell (Figure 
6B). Also, the concentration of 0,5 µM showed a slight decrease in cell viability, specialy in 
monocytes.  
These data lead us to exclud the highest concentration of celastrol (1 µM) from our 
experimental set-up and to select 0,3 µM and 0,5 µM of celastrol to be tested in following 
experiments. According to these data, we selected the 0,3 µM and 0,5 µM of celastrol, to be 
further tested with a range of LPS stimulus concentration (2 μg/mL, 5 μg/mL and 10 μg/mL) 
(Figure 7).  
 
   
1.1.3. CONCENTRATION OPTIMIZATION OF LPS 
 
We next proceeded to the alamarBlue® viability assay and we found that the Celastrol 
0,5 µM + LPS 2 μg/mL , Celastrol 0,5 µM + LPS 5 μg/mL and Celastrol 0,5 µM + LPS 10 
μg/mL incubation during 4h were the conditions which most affected the cell viability, 
exceeding the value that we defined as the cutoff (20% decrease in cell viability) of cell 
viability (Figure 7). Regarding the remaining conditions, we observed that Celastrol 0,3 µM 
+ LPS 2 μg/mL was the only condition with both stimuli that did not affect cell viability; in 
addition, none of the tested concentrations of Celastrol nor LPS markedly reduced cell 
viability. 
AlamarBlue ® viability assay – Cell viability analysis 
Figure 7 – Concentration optimization of celastrol with LPS in in vitro under incubation time of 4h. Cell viability analysis by 
alarmarBlue® assay. Data from the alarmarBlue® cell viability assay. Data are expressed as mean with standard deviation. 
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To assess how these conditions particularly could affect the viability of the 
subpopulations, we then performed a Flow Cytometry analysis (Figure 8).  
 
 
Flow Cytometry – Cell viability and subpopulation percentage analysis 
 
 
Incubation for 4h with Celastrol 0,3 µM + LPS 10 μg/mL was the condition with both 
stimuli that affected less both the lymphocytes (Figure 8A) and monocytes viability (Figure 
8B). Moreover, also in lymphocytes and monocytes, it was observed that Celastrol 0,3 µM 
appeared to affect less and increase, respectively, the cell viability of these populations. 
Regarding to the effect of the isolated concentration of LPS on the subpopulations, we found 
that, while in the lymphocytes the LPS 5 μg/mL condition seemed to be those which 
affected less the cell viability, in the monocytes it was the LPS 2 μg/mL condition that 
seemed to affect less the cell viability. Concerning to the granulocytes, we found that none 
of the tested conditions appeared to affect the viability (Figure 8C).  
We finally performed a 7-AAD Apoptosis Staining to analyze the cell death of each 
subpopulations by Flow Cytometry (Figure 9). 
 
 
Figure 8 – Concentration optimization of celastrol with LPS in in vitro under incubation time of 4h. Cell viability and subpopulation 
percentage analysis by Flow Cytometry. Data from the Flow Cytometry analysis. Data are expressed as mean with standard deviation. 
A B C 
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Flow Cytometry – Cell viability and subpopulation percentage analysis 
7-AAD Apoptosis Staining – Subpopulations cell death analysis 
 
Among the tested concentrations, we found that incubation for 4h with Celastrol 0,3 µM 
+ LPS 10 μg/mL was the condition that showed less lymphocyte’s, monocyte’s and 
granulocyte’s cell death, appearing to be the best experimental condition to be tested in the 
following experiments (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Concentration optimization of celastrol with LPS in in vitro under incubation time of 4h. Analysis of subpopulations cell death 
by 7-AAD Apoptosis Staining and Flow Cytometry. Data from the Flow Cytometry analysis. Data are expressed as mean with standard 
deviation. 
A B C 
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2. HUMAN SAMPLES  
 
2.1. CHARACTERIZATION OF PATIENTS COHORT 
 
 
A group of RA patients (n=5) with active disease (disease score > 3.2) and with more 
than 1 year of disease duration (Aletaha D et al., 2010), was included in this study. All RA 
patients were under MTX treatment and had a mean age of 74 ± 5 years old, all female, 
80% were RF positive, 40% were ACPA positive and DAS28 score was 4.5 ± 1.3. 
Additionally, blood samples were collected from healthy donors (n=10) for comparison. The 
clinical information from all patients and healthy controls included in this study is indicated 
in Table 1. 
 
       Table 1 - Clinical characterization about healthy controls and chronic RA patients. 
 
Controls 
(n = 10) 
Chronic RA patients 
(n = 5) 
Age (years) 39 ± 5 74 ± 5* 
Sex (% female) 70 100 
Disease duration (years) NA 10 ± 13 
RF-positive (%) ND 80 
ACPA-positive (%) ND 40 
CRP (mg/dL) ND 1.6 ± 1.3 
ESR (mm/1st hour) ND 36 ± 11 
Patient VAS NA 51 ± 17 
DAS28 NA 4.5 ± 1.3 
Tender joints NA 4 ± 4 
Swollen joints NA 4 ± 4 
Concomitant treatment:   
    MTX NA 1 / 5 
    MTX + PDN NA 1 / 5 
    MTX + DFZ NA 2 / 5 
    MTX + PDN + SLZ NA 1 / 5 
    No treatment NA 0 / 5 
RA – Rheumatoid Arthritis; RF – Rheumatoid Factor; ACPA – Anti-Citrullinated 
Protein Antibody; CRP – C-reactive protein; ESR – Erythrocyte Sedimentation 
Rate; VAS – Visual Analogue Scale; DAS28 – Disease Activity Score of 28 
joints; MTX – Methotrexate; PDN – Prednisone; DFZ – Deflazacort; SLZ – 
Salazopyrin; ND – not determined; NA – not applicable. Values are 
represented as mean ± standard deviation. *Differences were considered 
statistically significant for p-values < 0.05 according to the Mann-Whitney 
test. 
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3. FLOW CYTOMETRY   
 
3.1. HEALTHY CONTROLS  
 
3.1.1. MONOCYTES  
 
 
 Classification of monocyte subpopulations and the effect of celastrol 
 
A gate was defined around total monocytes in peripheral leukocytes, depending upon 
cell size (forward scatter) and granularity (side scatter). Total monocytes were identified 
based on the expression of the cell surface marker CD14, excluding CD3 expression, and 
gating out cell aggregates and dead cells through by FVD marker. Monocytes can be 
subdivided into three subpopulations based on their expression of CD14 and CD16 surface 
markers and classified as classical (CD14+CD16-), intermediate (CD14+CD16+) and non-
classical (CD14dimCD16+) monocytes (Cros J et al., 2010).  
The frequency of monocyte subsets was determined according to this classification 
system, although in this thesis the graphs presented are only relative to total CD14+ 
monocyte cells, due to the higher number of acquired cells, contrary to the insufficient cell 
events acquired in the gate of subpopulations. Of note, the analysis of all monocyte 
subpopulations was excluded in order not to lead to wrong interpretations. However, the 
graphs related to monocyte subpopulations are annexed as Appendix (Appendix II).   
 
Total CD14+ cells 
 
The analysis of the frequency (%) of total CD14+ cells has revealed that statistically 
significant differences were found between the tested conditions in healthy controls.  
Specifically, it was observed that Celastrol (p=0.0008) and Celastrol + LPS (p=0.0015) 
significantly increased the levels of total CD14+ cells in comparison to LPS and restored the 
levels to basal levels (Figure 10). 
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 Monocyte markers and the effect of celastrol  
 
The expression of several cellular markers was analyzed to characterize the effect of 
celastrol on monocytes phenotype in healthy controls.  
Classical activation monocyte markers (HLA-DR, CD16, CD86) were used and 
according to their function: HLA-DR (determined by % of positive cells and MFI values) - 
function as antigen-presenting cell (APC) as well as T-cell costimulation; CD16 (% and 
MFI) - activation and its phagocytic potential / the mediation of immunophagocytosis; 
CD86 (% and MFI) - monocyte-T cell costimulatory signalling required for T cell 
activation. CD115 (% and MFI) - receptor for macrophage-colony stimulating factor (M-
CSF), essential for osteocastogenesis process; the receptor activator of nuclear factor-kB 
(NF-kB) (RANK) (% and MFI) - participates in osteoclast activation, differentiation and 
survival (osteoclastogenesis) and bone resorption. 
 
 
Figure 10 – Frequency of total CD14+ cells from healthy controls is 
significantly reduced with LPS condition in comparison to Media + Ethanol 
and significantly increased with Celastrol and Celastrol + LPS in comparison 
to LPS. Data from flow cytometry analysis of peripheral blood monocyte cells 
from healthy controls tested with several conditions. Data are expressed as 
median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
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CD16  
 
Regarding CD16, it was observed that Celastrol (p=0.0080) significantly reduced the 
levels of CD16+ cells on total CD14+ cells in comparison to Media + Ethanol, and Celastrol 
+ LPS significantly reduced the levels in comparison to Media + Ethanol (p<0.0001), LPS 
(p=0.0007) and Celastrol (p=0.0006) (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, it was observed that Celastrol + LPS significantly reduced the expression of 
CD16 MFI values on total CD14+ cells in comparison to Media + Ethanol (p<0.0001), LPS 
(p=0.0225) and Celastrol (p=0.0003) (Figure 12).  
 
 
Figure 11 – Frequency of CD16+ cells on total CD14+ cells from healthy 
controls is significantly reduced with Celastrol and LPS conditions in 
comparison to Media + Ethanol, and significantly reduced with Celastrol + 
LPS condition in comparison to Media + Ethanol, LPS and Celastrol. Data 
from flow cytometry analysis of peripheral blood monocyte cells from 
healthy controls tested with several conditions. Data are expressed as 
median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests.  
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CD86  
 
The analysis of CD86 on monocytes has revelead that Celastrol (p=0.0074) significantly 
increased the frequencies of CD86+ cells on total CD14+ cells in comparison to LPS and 
restored the frequencies to basal levels. Celastrol + LPS significantly reduced the 
frequencies in comparison to Media + Ethanol (p=0.0009) and Celastrol (p=0.0021) (Figure 
13). 
Figure 12 – Expression of CD16 (MFI) cell marker on total CD14+ cells from healthy 
controls is significantly reduced with LPS in comparison to Media + Ethanol, and 
also significantly reduced with Celastrol + LPS in comparison to Media + Ethanol, 
LPS and Celastrol. Data from flow cytometry analysis of peripheral blood 
monocytes from healthy controls tested with several conditions. Data are 
expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
33 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Furthermore, significant differences were found in CD86 MFI values on total CD14+ 
cells. 
Particularly, it was observed that Celastrol (p=0.0076) significantly increased the 
expression of CD86 MFI values on total CD14+ cells in comparison to LPS and restored the 
MFI values to basal levels. Celastrol + LPS significantly reduced the expression in 
comparison to Media + Ethanol (p=0.0007) and Celastrol (p=0.0101) (Figure 14).   
Figure 13 – Frequency of CD86+ cells on total CD14+ cells from healthy 
controls is significantly increased with Celastrol condition in comparison to 
LPS, and significantly reduced with Celastrol + LPS in comparison to Media + 
Ethanol and Celastrol. Data from flow cytometry analysis of peripheral blood 
monocyte cells from healthy controls tested with several conditions. Data 
are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests.  
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HLA-DR  
 
Respectively to the HLA-DR expression, there were no significant differences in the 
levels of HLA-DR+ cells on total CD14+ cells in all tested conditions (data not shown)  
Furthermore, significant differences were found in HLA-DR MFI values on total CD14+ 
cells. 
Specifically, it was observed that Celastrol (p=0.0293) significantly reduced the 
expression of HLA-DR MFI cell marker on total CD14+ cells in comparison to LPS and 
restored the MFI values to basal levels. Celastrol + LPS significantly reduced the expression 
in comparison to Media + Ethanol (p=0.0155) and LPS (p=0.0047) (Figure  15). 
 
 
Figure 14 – Expression of CD86 (MFI) cell marker on total CD14+ cells from healthy 
controls is significantly reduced with LPS in comparison to Media + Ethanol, and 
also significantly reduced with Celastrol + LPS in comparison to Media + Ethanol 
and Celastrol, and significantly increased with Celastrol in comparison to LPS. Data 
from flow cytometry analysis of peripheral blood monocytes from healthy controls 
tested with several conditions. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
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CD115  
 
Concerning to the expression of CD115, there were significant differences in the levels 
of CD115+ cells on total CD14+ cells. 
Specifically, it was observed that Celastrol (p=0.0063) significantly reduced the 
frequencies of CD115+ cells on total CD14+ cells in comparison to Media + Ethanol, and 
Celastrol + LPS significantly reduced the frequencies in comparison to Media + Ethanol 
(p<0.0001), LPS (p=0.0110) and Celastrol (p=0.0021) (Figure 16). 
 
 
 
 
 
Figure 15 – Expression of HLA-DR (MFI) cell marker on total CD14+ cells from 
healthy controls is significantly reduced with Celastrol and Celastrol + LPS in 
comparison to LPS, and also significantly reduced with Celastrol + LPS in 
comparison to LPS, and significantly increased with LPS in comparison to Media + 
Ethanol. Data from flow cytometry analysis of peripheral blood monocytes from 
healthy controls tested with several conditions. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, significant differences were found in CD115 MFI values on total CD14+ 
cells. 
Particularly, it was observed that Celastrol (p=0.0021) significantly reduced the 
expression of CD115 MFI cell marker on total CD14+ cells in comparison to Media + 
Ethanol, and Celastrol + LPS significantly reduced the expression in comparison to Media + 
Ethanol (p<0.0001), LPS (p=0.0160) and Celastrol (p=0.0039) (Figure 17). 
Figure 16 – Frequency of CD115+ cells on total CD14+ cells from healthy 
controls is significantly reduced with LPS and Celastrol conditions in 
comparison to Media + Ehanol, and also significantly reduced with Celastrol + 
LPS in comparison to Media + Ethanol, LPS and Celastrol. Data from flow 
cytometry analysis of peripheral blood monocyte cells from healthy controls 
tested with several conditions. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests.  
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RANK 
 
The analysis of RANK has revelead that no significant differences were observed in the 
levels of RANK+ cells and in RANK MFI values on total CD14+ cells (data not shown). 
 
 
 
 
 
 
 
 
Figure 17 – Expression of CD115 (MFI) cell marker on total CD14+ cells from 
healthy controls is significantly reduced with LPS, Celastrol and Celastrol + LPS in 
comparison to Media + Ethanol, and also significantly reduced with Celastrol + LPS 
in comparison to LPS and Celastrol. Data from flow cytometry analysis of 
peripheral blood monocytes from healthy controls tested with several conditions. 
Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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3.1.2. GRANULOCYTES  
 
 
 Classification of granulocyte population and the effect of celastrol 
 
A gate was defined around total granulocytes in peripheral leukocytes, depending upon 
cell size (forward scatter) and granularity (side scatter). Total granulocytes were identified 
based on the expression of the cell surface marker CD66b and gating out cell aggregates and 
dead cells through by FVD marker. 
 
 
Total CD66b+ cells  
 
The analysis of the frequency (%) of total CD66b+ cells has revealed that no statistically 
significant differences were found between the tested conditions in healthy controls (data not 
shown). 
 
 
 Granulocyte markers and the effect of celastrol 
 
The expression of several cellular markers was analyzed to characterize granulocyte 
phenotype upon celastrol incubation in healthy controls.  
Activation and adhesion markers were used: CD11b (% and MFI) - granulocyte 
activation, adhesion as well as chemotaxis and phagocytosis; CD15 (% and MFI) - 
activation and granulocyte adhesion; CD62L (MFI), also known as L-selectin - granulocyte 
adhesion to inflammatory tissue. CD16 (MFI) - phagocytic potencial of granulocytes / the 
mediation of immunophagocytosis; CXCR2 (% and MFI), the major neutrophil/granulocyte 
chemoattractant receptor, also known as IL-8 receptor,beta (IL-8Rβ) - migration to 
inflammatory sites. 
 
CD11b  
 
We have observed no significant differences on the levels of CD11b+ cells on total 
CD66b+ cells, in all tested conditions (data not shown). However, it was observed that 
Celastrol (p=0.0047) significantly reduced the expression of CD11b MFI values on total 
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CD66b+ cells in comparison to LPS and restored the MFI values to basal levels. Celastrol + 
LPS significantly increased the MFI values in comparison to Media + Ethanol (p=0.0040) 
and Celastrol (p=0.0029) (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD15 
 
The analysis of CD15 has revelead that no significant differences exist in the levels of 
CD15+ cells and in CD15 MFI values on total CD66b+ cells (data not shown).  
 
 
CD16 
 
Respectively to the CD16 expression, there were no significant differences (data not 
shown). 
 
 
Figure 18 – Expression of CD11b (MFI) cell marker on CD66b+ cells from 
healthy controls is significantly increased with LPS and Celastrol + LPS 
conditions in comparison to Media + Ethanol, and also significantly increased 
with Celastrol + LPS in comparison to Celastrol, and significantly reduced with 
Celastrol in comparison to LPS. Data from flow cytometry analysis of peripheral 
blood granulocytes cells from healthy controls tested with several conditions. 
Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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CD62L 
 
Regarding to the analysis of CD62L, it was observed that Celastrol (p=0.0041) and 
Celastrol + LPS (p=0.0089) significantly reduced the expression of CD62L MFI values on 
total CD66b+ cells in comparison to Media + Ethanol (Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCR2 
 
We have observed that Celastrol (p=0.0420) and Celastrol + LPS (p=0.0496) 
significantly reduced the frequencies of CXCR2+ cells on total CD66b+ cells in comparison 
to LPS and restored the frequencies to basal levels (Figure 20).  
 
Figure 19 – Expression of CD62L (MFI) cell marker on CD66b+ cells from 
healthy controls is significantly reduced with Celastrol and Celastrol + LPS 
conditions in comparison to Media + Ethanol. Data from flow cytometry 
analysis of peripheral blood granulocytes cells from healthy controls tested 
with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according 
to the Mann-Whithey tests. 
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However, no significant differences were observed in CXCR2 MFI values on total 
CD66b+ cells (data not shown).  
 
 
 
 
 
 
 
 
 
 
Figure 20 – Frequencies of CXCR2+ cells on total CD66b+ cells from healthy 
controls is significantly increased with LPS in comparison to Media + Ethanol, 
and significantly reduced with Celastrol and Celastrol + LPS in comparison to 
LPS. Data from flow cytometry analysis of peripheral blood granulocytes cells 
from healthy controls tested with several conditions. Data are expressed as 
median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
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3.1.3. T CELLS 
 
 
 Classification of T cell subpopulations and the effect of celastrol 
 
A gate was defined around total lymphocytes in peripheral leukocytes, depending upon 
cell size (forward scatter) and granularity (side scatter). Total T cells were identified based 
on the expression of the cell surface marker CD3 and gating out cell aggregates and dead 
cells through by FVD marker. T cell subpopulations were subdivided into two main subsets 
(gated in CD3), according to their CD4 and CD8 expression and classified as T helper cells 
(Th) (CD3+CD4+) and T cytotoxic cells (Tc) (CD3+CD8+). 
Additionaly, T helper cells can be classified from naïve T helper cells into four major 
lineages: Th1, Th2, Th17, and regulatory T (Treg) cells. Each T helper cell subset exhibits 
characteristic functions, patterns of cytokine secretion, and expression of specific chemokine 
receptors.  
T helper cell subsets (gated in CD3+CD4+) were classified as naïve (CD45RO-HLA-
DR-), naïve activated (CD45RO-HLA-DR+), memory (CD45RO+HLA-DR-) and 
memory activated (CD45RO+HLA-DR+) T cells. To study regulatory T (Treg) cells 
(gated in CD3+CD4+), they were classified according to CD25 and Foxp3 expression 
(CD25+Foxp3+ subset). In addition, Treg cell analysis (gated in CD3+CD4+) was still 
discriminated according to the levels of CD25 expression and Treg cells classified as 
CD25dim (CD4+CD25dim), CD25intermediate (CD4+CD25int) and CD25bright (CD4+CD25bright) 
cells. Moreover, it was also accessed the frequency of three T helper cell subsets (gated in 
CD3+CD4+) based on the CD45RO and CCR7 expression and they were classified as naïve 
(CD45RO-CCR7+), central memory (CD45RO+CCR7+) and effector memory 
(CD45RO+CCR7-) T cells. In order to study central memory T cells (CD45RO+CCR7+) 
(gated in CD3+CD4+), they were classified as Th1-like (CXCR3+CCR6-), Th2-like 
(CXCR3-CCR6-) and Th17-like (CXCR3-CCR6+) cells. Likewise, in order to study 
effector memory T cells (CD45RO+CCR7-) (gated in CD3+CD4+), they were classified as 
Th1-like (CXCR3+CCR6-), Th2-like (CXCR3-CCR6-) and Th17-like (CXCR3-CCR6+) 
cells. 
Concerning to the T cytotoxic cell subsets (gated in CD3+CD8+) they were classified 
as naïve (CD45RO-HLA-DR-), naïve activated (CD45RO-HLA-DR+), memory 
(CD45RO+HLA-DR-) and memory activated (CD45RO+HLA-DR+) T cells. 
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The frequency of T cell subsets was determined according to these classification 
systems, although in this thesis the graphs presented are only relative to total CD3+ T cells, 
due to the insufficient cell counts acquired in the gate of each subpopulation. The graphs 
related to T cell subpopulations are annexed as Appendix (Appendix III). 
 
 
Total CD3+ T cells and the main T cell subpopulations (CD4+ and CD8+)   
 
The analysis of the frequency (%) of total CD3+ T cells has revealed that no statistically 
significant differences were found between the tested conditions in healthy controls (data not 
shown). Additionally, there were no significant differences in the levels of the main T cell 
subpopulations (T helper cells (CD3+CD4+) and T cytotoxic cells (CD3+CD8+)) in all 
conditions (data not shown). 
 
T helper cell subpopulations (CD3+CD4+) 
 
We have observed that Celastrol (p=0.0120) significantly reduced the levels of naïve 
activated T cells in comparison to LPS and restored the levels to basal levels. Celastrol + 
LPS significantly increased the levels in comparison to Media + Ethanol (p=0.0349) and 
Celastrol (p=0.0433) (Appendix III.1). 
There were no significant differences in the levels of regulatory T (Treg) cells 
(CD25+Foxp3+ subset), in all tested conditions (data not shown). Additionally, no 
significant differences were found in the levels of CD25 subpopulations (CD25dim, 
CD25intermediate and CD25bright) of regulatory T (Treg) cells, in all conditions (data not 
shown). 
Furthermore, there were no significant differences in the levels of the T helper cell 
subpopulations based on the CD45RO and CCR7 expression (naïve (CD45RO-CCR7+), 
central memory (CD45RO+CCR7+) and effector memory (CD45RO+CCR7-) T cells), in all 
tested conditions (data not shown).  
Additionaly, no significant differences were found in the levels of central memory and 
effector memory T cell subpopulations, in all conditions (data not shown), except in central 
memory and effector memory Th2-like cells (CXCR3-CCR6-).  
Specifically, it was observed that Celastrol significantly increased the levels of central 
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memory Th2-like cells in comparison to Media + Ethanol (p=0.0071) and LPS (p=0.0460), 
and Celastrol + LPS significantly increased the levels in comparison to Media + Ethanol 
(p=0.0001) and LPS (p=0.0030) (Appendix III.2). Also, it was observed that Celastrol 
(p=0.0195) significantly increased the levels of effector memory Th2-like cells in 
comparison to Media + Ethanol, and Celastrol + LPS significantly increased the levels in 
comparison to Media + Ethanol (p=0.0005) and LPS (p=0.0310) (Appendix III.3). 
 
T cytotoxic cell subpopulations (CD3+CD8+) 
 
Regarding to the analysis of the T cytotoxic (CD3+CD8+) cell subpopulations, no 
significant differences were found in the frequency of the cell subpopulations analyzed 
(naïve (CD45RO-HLA-DR-), naïve activated (CD45RO-HLA-DR+), memory 
(CD45RO+HLA-DR-) and memory activated (CD45RO+HLA-DR+) T cytotoxic cells), in 
all tested conditions (data not shown). 
 
 
 T cell markers and the effect of celastrol  
 
The expression of several cellular markers was analyzed to characterize T cell 
phenotype after incubation with celastrol in healthy controls.  
Activation T cell markers were used: HLA-DR (MFI) - T cell activation; CD40L (MFI) 
- T cell activation and B-cell costimulation; CD25 (%) - T cell activation and particularly, 
the ability of Treg cells to exert suppressive or effector effects. Foxp3 (% and MFI) - 
suppressive effect of Treg cells (ability of Treg cells to suppress effector T-cell proliferation 
and cytokine secretion) and the correlation with disease severity; CD45RO (%) - memory T 
cells; RORgT (MFI) - differentiation of Th17 cells; CCR6 (% and MFI) - chemotaxis 
(migration) and recruitment of memory Th17 cells (producer of IL-17) to target tissues; 
CXCR3 (% and MFI) - chemotaxis (migration) and recruitment of memory Th1 cells to 
target tissues; CCR7 (% and MFI) - chemotaxis (migration) and recruitment of naïve or 
central memory Th cells to target tissues. 
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HLA-DR  
 
No significant differences were found in HLA-DR MFI values on total CD3+ T cells and 
the main T cell subpopulations (T helper cells (CD3+CD4+) and T cytotoxic cells 
(CD3+CD8+)) analyzed, in all tested conditions (data not shown).  
 
CD40L  
 
The analysis of the expression of CD40L has revelead that there were no significant 
differences in CD40L MFI values on total CD3+ T cells and the main T cell subpopulations 
analyzed, in all tested conditions. 
 
RORgT  
 
No significant differences were found in RORgT MFI values on T helper cells 
(CD3+CD4+), in all tested conditions (data not shown). 
 
Foxp3  
 
There were no significant differences in Foxp3 MFI values on regulatory T (Treg) cells 
(CD25+Foxp3+ subset) and on CD25 subpopulations (CD25dim, CD25intermediate and 
CD25bright) of regulatory T (Treg) cells, in all tested conditions (data not shown). 
 
CCR7  
 
No significant differences were observed in CCR7 MFI values on total CD3+ T cells and 
on T helper cells (CD3+CD4+), in all tested conditions (data not shown). 
 
CCR6  
 
There were no significant differences in CCR6 MFI values on total CD3+ T cells and on T 
helper cells (CD3+CD4+), in all tested conditions (data not shown). 
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CXCR3  
 
We have observed that Celastrol (p=0.0107) significantly reduced the expression of 
CXCR3 MFI values on total CD3+ T cells in comparison to Media + Ethanol, and Celastrol 
+ LPS significantly reduced the expression in comparison to Media + Ethanol (p=0.0002), 
LPS (p=0.0029) and Celastrol (p=0.0197) (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Also, it was observed that Celastrol + LPS significantly reduced the expression of 
CXCR3 MFI values on T helper cells (CD3+CD4+) in comparison to Media + Ethanol 
(p=0.0368) and LPS (p=0.0312) (Appendix III.4). 
 
 
 
 
Figure 21 – Expression of CXCR3 (MFI) cell marker on total CD3+ T cells from 
healthy controls is significantly reduced with Celastrol in comparison to Media + 
Ethanol, and is also significantly reduced with Celastrol + LPS in comparison to 
Media + Ethanol, LPS and Celastrol. Data from flow cytometry analysis of 
peripheral blood T cells from healthy controls tested with several conditions. Data 
are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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3.1.4. B CELLS 
 
 
 Classification of B cell subpopulations and the effect of celastrol 
 
A gate was defined around total lymphocytes in peripheral leukocytes, depending upon 
cell size (forward scatter) and granularity (side scatter). Total B cells were identified based 
on the expression of the cell surface marker CD19, gating out cell aggregates and dead cells 
through by FVD marker, and its subpopulations were classified using three classification 
systems (gated in CD19): according to IgD and CD27 expression - naïve B cells 
(IgD+CD27-), pre-switch memory (IgD+CD27+), post-switch memory (IgD-CD27+) and 
double-negative (DN) (IgD-CD27-) B cells (Moura RA et al., 2017); according to IgD and 
CD38 expression – transitional (IgD+CD38++) B cells and plasmablasts (IgD-CD38++) 
(Moura RA et al., 2017); and according to CD21 and CD38 expression – activated B cells 
(CD21lowCD38low) (Wehr C et al., 2008).  
Although an analysis with these classification systems has been performed in the 
present work to define B cell subpopulations, the graphs with significantly results presented 
in this thesis are only relative to total CD19+ B cells, while that graphs related to its 
subpopulations are annexed as Appendix (Appendix IV). This is due to the low number of 
cell counts obtained in some samples during data acquisition, which limited the analysis 
robustness of several B cell subpopulations. 
 
 
Total CD19+ B cells and B cell subpopulations  
 
The analysis of the frequency (%) of total CD19+ B cells has revealed that no 
statistically significant differences were found between the tested conditions in healthy 
controls (data not shown). Additionally, there were no significant differences in the levels of 
the B cell subpopulations (naïve, pre-switch memory, post-switch memory, double-negative 
B cells and transitional B cells, plasmablasts – according to the IgD/CD27 and IgD/CD38 
classification system, respectively) in all conditions (data not shown). 
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 B cell markers and the effect of celastrol 
 
The expression of several cellular markers was analyzed to characterize B cell 
phenotype upon celastrol incubation for 4h in healthy controls.  
B cell markers were used according to their function: BAFF-R (% and MFI) - activation 
and survival; HLA-DR (% and MFI) - activation and its function as antigen-presentation cell 
(APC) as well as T-cell costimulation; CD21 (% and MFI) - immature B cells and 
complement system activation (CD21low, autoimmunity); CD38 (MFI) - adhesion, 
activation, and calcium signaling; CD32 or FcgRIIB (MFI) - inhibition; RANKL (% and 
MFI) - osteoclast activation, differentiation and survival (osteoclastogenesis) and bone 
resorption; CD95 (% and MFI), also known as Fas receptor (FasR) - Fas-mediated 
apoptosis. 
 
BAFF-R  
 
We have observed that no significant differences exist in the frequency of BAFF-R+ 
cells and in BAFF-R MFI values on total CD19+ B cells and in all B cell subpopulations, in 
all tested conditions (data not shown). 
 
FcgRIIB  
 
Regarding FcgRIIB, no significant differences were found in FcgRIIB MFI values on 
total CD19+ B cells and all B cell subpopulations analyzed (data not shown), except in 
plasmablasts (IgD-CD38++). We observed that Celastrol (p=0.0047) and Celastrol + LPS 
(p=0.0176) significantly reduced the expression of FcgRIIB MFI cell marker in peripheral 
plasmablasts in comparison to LPS and restored the MFI values to basal levels (Appendix 
IV.1). 
 
CD38  
 
The analysis of CD38 has revelead that no significant differences were observed in CD38 
MFI values on total CD19+ B cells and all B cell subpopulations analyzed, in all tested 
conditions (data not shown). 
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CD21  
 
Respectively to the CD21 expression, there were no significant differences in the levels 
of CD21+ cells on total CD19+ B cells and all B cell subpopulations analyzed, in all tested 
conditions (data not shown). 
Moreover, it was observed that Celastrol (p=0.0415) significantly increased the 
expression of CD21 MFI cell marker on total CD19+ B cells, in comparison to LPS and 
restored the MFI values to basal levels (Figure 22). However, no significant differences 
were found in CD21 MFI values on the remaining B cell subpopulations analyzed, in all 
tested conditions (data not shown), except in naïve B cells (IgD+CD27-). Herein, it was 
observed that Celastrol (p=0.0490) significantly increased the expression of CD21 MFI cell 
marker in peripheral naïve B cells in comparison to LPS (Appendix IV.2).  
 
 
 
 
 
 
 
 
 
 
CD21lowCD38low 
 
Concerning to the expression of CD21lowCD38low, there were no significant differences 
in the levels of CD21lowCD38low+ cells on total CD19+ B cells, in all tested conditions (data 
not shown).   
 
 
Figure 22 – Expression of CD21 (MFI) cell marker on total CD19+ B cells from 
healthy controls is significantly increased with Celastrol condition in comparison to 
LPS. Data from flow cytometry analysis of peripheral blood B cells from healthy 
controls tested with several conditions. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
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HLA-DR 
 
The analysis of HLA-DR has revelead that no significant differences were observed in 
the levels of HLA-DR+ cells on total CD19+ B cells and all B cell subpopulations analyzed, 
in all tested conditions (data not shown), except in transitional B cells (IgD+CD38++). 
Herein, it was observed that Celastrol + LPS (p=0.0230) significantly increased the 
frequencies of HLA-DR+ cells on transitional B cells in comparison to LPS and restored the 
frequencies to basal levels (Appendix IV.3). Furthermore, no significant differences were 
found in HLA-DR MFI values on total CD19+ B cells and all B cell subpopulations 
analyzed, in all tested conditions (data not shown). 
 
RANKL 
 
Regarding to the analysis of RANKL, there were significant differences in the levels of 
RANKL+ cells on total CD19+ B cells and all B cell subpopulations analyzed, in all tested 
conditions, except in double-negative B cells (IgD-CD27-) and plasmablasts (IgD-CD38++) 
(data not shown). 
Specifically, it was observed that Celastrol (p=0.0278) significantly reduced the 
frequencies of RANKL+ cells on total CD19+ B cells in comparison to LPS and restored the 
frequencies to basal levels (Figure 23).  
 
 
 
 
 
 
 
 
 
Figure 23 – Frequency of RANKL+ cells on total CD19+ B cells from healthy 
controls is significantly reduced with Celastrol condition in comparison to 
LPS. Data from flow cytometry analysis of peripheral blood B cells from 
healthy controls tested with several conditions. Data are expressed as 
median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
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Similarly, it was observed that Celastrol significantly reduced the frequencies of 
RANKL+ cells on naïve B cells (IgD+CD27-) (p=0.0420) (Appendix IV.4), pre-switch 
memory (IgD+CD27+) (p=0.0140) (Appendix IV.5) and on post-switch memory (IgD-
CD27+) (p=0.0177) (Appendix IV.6) in comparison to LPS and restored these frequencies 
to basal levels. And lastly, it was observed that Celastrol significantly reduced the 
frequencies of RANKL+ cells on transitional B cells (IgD+CD38++) in comparison to 
Media + Ethanol (p=0.0371) and LPS (p=0.0062) (Appendix IV.7). 
Furthermore, no significant differences were found in RANKL MFI values on total 
CD19+ B cells and all B cell subpopulations analyzed, in all tested conditions (data not 
shown). 
 
CD95 
 
Respectively to the CD95 expression, there were no significant differences in the levels 
of CD95+ cells on total CD19+ B cells and all B cell subpopulations analyzed, in all tested 
conditions (data not shown), except in naïve B cells, transitional B cells and plasmablasts. 
Specifically, it was observed that Celastrol (p=0.0175) significantly reduced the 
frequencies of CD95+ cells on naïve B cells (IgD+CD27-) in comparison to LPS and 
restored the frequencies to basal levels (Appendix IV.8). Similarly, it was observed that 
Celastrol significantly reduced the frequencies of CD95+ cells on transitional B cells 
(IgD+CD38++) in comparison to Media + Ethanol (p=0.0220) and LPS (p=0.0040) 
(Appendix IV.9). Also, it was observed that Celastrol (p=0.0190) significantly reduced the 
frequencies of CD95+ cells on plasmablasts (IgD-CD38++) in comparison to LPS and 
restored the frequencies to basal levels (Appendix IV.10).  
Furthermore, no significant differences were found in CD95 MFI values (data not 
shown), except in naïve B cells, transitional B cells and plasmablasts.  
We have observed that Celastrol (p=0.0155) significantly reduced the expression of 
CD95 MFI values on naïve B cells (IgD+CD27-) in comparison to Media + Ethanol 
(Appendix IV.11). In addition, it was observed that Celastrol (p=0.0068) and Celastrol + 
LPS (p=0.0349) significantly reduced the expression of CD95 MFI values on transitional B 
cells (IgD+CD38++) in comparison to Media + Ethanol (Appendix IV.12). Also, it was 
observed that Celastrol (p=0.0190) significantly reduced the expression of CD95 MFI values 
on plasmablasts (IgD-CD38++) in comparison to LPS and restored the MFI values to basal 
levels (Appendix IV.13). 
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3.2. CHRONIC RA PATIENTS 
 
3.2.1. MONOCYTES  
 
 
 Effect of celastrol on monocyte population 
 
 
Total CD14+ cells 
 
The analysis of the frequency of total CD14+ cells has revealed that no statistically 
significant differences were found between the tested conditions in chronic RA patients 
(data not shown).  
 
 Effect of celastrol on monocyte markers 
 
 
CD16 
 
Regarding CD16, no significant differences were observed in the levels of CD16+ cells 
and in CD16 MFI values on total CD14+ cells in all tested conditions (data not shown). 
 
CD86  
 
The analysis of the expression of CD86 has revelead that Celastrol + LPS (p=0.0159) 
significantly reduce the frequencies of CD86+ cells on total CD14+ cells in comparison to 
Media + Ethanol (Figure 24). 
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Furthermore, no significant differences were found in CD86 MFI values on total CD14+ 
cells (data not shown). 
 
HLA-DR  
 
Respectively to the HLA-DR expression, there were no significant differences in the 
levels of HLA-DR+ cells and in HLA-DR MFI values on total CD14+ cells (data not 
shown). 
 
CD115  
 
Concerning to the expression of CD115, it was observed that Celastrol (p=0.0079) and 
Celastrol + LPS (p=0.0079) significantly reduced the frequencies of CD115+ cells on total 
CD14+ cells in comparison to Media + Ethanol (Figure 25). 
 
Figure 24 – Frequency of CD86+ cells on total CD14+ cells from chronic RA 
patients is significantly reduced with LPS and Celastrol + LPS in comparison to 
Media + Ethanol. Data from flow cytometry analysis of peripheral blood 
monocyte cells from healthy controls tested with several conditions. Data 
are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests.  
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Furthermore, no significant differences were found in CD115 MFI values on total 
CD14+ cells (data not shown).  
 
 
RANK 
 
The analysis of the expression of RANK has revelead that no significant differences 
were observed in the levels of RANK+ cells and in RANK MFI values on total CD14+ cells 
(data not shown). 
 
 
 
 
Figure 25 – Frequency of CD115+ cells on total CD14+ cells from chronic RA 
patients is significantly reduced with LPS, Celastrol and Celastrol + LPS 
conditions in comparison to Media + Ehanol. Data from flow cytometry 
analysis of peripheral blood monocyte cells from healthy controls tested with 
several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests.  
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3.2.2. GRANULOCYTES  
 
 
 Effect of celastrol on granulocyte population 
 
 
Total CD66b+ cells 
 
The analysis of the frequency of total CD66b+ cells has revealed that no statistically 
significant differences were found between the tested conditions in chronic RA patients 
(data not shown). 
 
 
 
 Effect of celastrol on granulocyte markers 
 
 
CD11b  
 
Regarding to the analysis of CD11b, no significant differences were observed in its levels 
on total CD66b+ cells (data not shown). However, it was observed that Celastrol (p=0.0047) 
significantly reduced the expression of CD11b MFI values on total CD66b+ cells in 
comparison to LPS and restored the MFI values to basal levels (Figure 26).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 – Expression of CD11b (MFI) cell marker on CD66b+ cells from 
chronic RA patients is significantly increased with LPS in comparison to Media + 
Ethanol and significantly reduced with Celastrol in comparison to LPS. Data 
from flow cytometry analysis of peripheral blood granulocytes cells from 
chronic RA patients tested with several conditions. Data are expressed as 
median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
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CD15 
 
The analysis of the expression of CD15 has revelead that no significant differences were 
observed in the levels of CD15+ cells and in CD15 MFI values on total CD66b+ cells (data 
not shown). 
 
 
CD16 
 
Respectively to the CD16 expression, there were no significant differences (data not 
shown).  
 
 
CD62L 
 
Regarding to the analysis of CD62L, there were no significant differences in the CD62L 
MFI values on total CD66b+ cells (data not shown). 
 
CXCR2 
 
Respectively to the CXCR2 expression, there were no significant differences in the levels 
of CXCR2+ cells and in CXCR2 MFI values on total CD66b+ cells (data not shown). 
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3.2.3. T CELLS  
 
 
 Effect of celastrol on T cell subpopulations 
 
 
Total CD3+ T cells and the main T cell subpopulations (CD4+ and CD8+) 
 
The analysis of the frequency of total CD3+ T cells has revealed that no statistically 
significant differences were found between the tested conditions in chronic RA patients 
(data not shown). Additionally, there were no significant differences in the levels of the 
main T cell subpopulations (T helper cells (CD3+CD4+) and T cytotoxic cells 
(CD3+CD8+)) in all conditions (data not shown). 
 
 
T helper cell subpopulations (CD3+CD4+) 
 
We have observed that Celastrol (p=0.0317) significantly increased the levels of memory 
activated T cells in comparison to Media + Ethanol (Appendix III.5).  
There were no significant differences in the levels of regulatory T (Treg) cells 
(CD25+Foxp3+ subset) (data not shown). Additionally, no significant differences were 
found in the levels of CD25 subpopulations (CD25dim, CD25intermediate and CD25bright) of 
regulatory T (Treg) cells (data not shown). 
Furthermore, there were no significant differences in the levels of the T helper cell 
subpopulations based on the CD45RO and CCR7 expression (naïve (CD45RO-CCR7+), 
central memory (CD45RO+CCR7+) and effector memory (CD45RO+CCR7-) T cells) (data 
not shown).  
Additionaly, no significant differences were found in the levels of central memory and 
effector memory T cell subpopulations (Th1-like (CXCR3+CCR6-), Th2-like (CXCR3-
CCR6-) and Th17-like (CXCR3-CCR6+) cells) (data not shown).  
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T cytotoxic cell subpopulations (CD3+CD8+) 
 
Regarding to the analysis of the T cytotoxic (CD3+CD8+) cell subpopulations, no 
significant differences were found in the frequency of the cell subpopulations analyzed 
(naïve (CD45RO-HLA-DR-), naïve activated (CD45RO-HLA-DR+), memory 
(CD45RO+HLA-DR-) and memory activated (CD45RO+HLA-DR+) T cytotoxic cells) 
(data not shown). 
 
 Effect of celastrol on T cell markers 
 
 
HLA-DR  
 
Regarding to the analysis of HLA-DR, no significant differences were found in HLA-
DR MFI values on total CD3+ T cells and the main T cell subpopulations (T helper cells 
(CD3+CD4+) and T cytotoxic cells (CD3+CD8+)) analyzed (data not shown). CORRECTO 
 
CD40L  
 
The analysis of the expression of CD40L has revelead that no significant differences 
were observed in CD40L MFI values on total CD3+ T cells and the main T cell 
subpopulations analyzed.  
 
RORgT  
 
Respectively to the RORgT expression, there were no significant differences in RORgT 
MFI values on T helper cells (CD3+CD4+) (data not shown). 
 
Foxp3  
 
Concerning to the expression of Foxp3, there were no significant differences in Foxp3 
MFI values on regulatory T (Treg) cells (CD25+Foxp3+ subset) and on CD25 subpopulations 
(CD25dim, CD25intermediate and CD25bright) of regulatory T (Treg) cells (data not shown). 
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CCR7  
 
The analysis of CCR7 has revelead that no significant differences were observed in 
CCR7 MFI values on total CD3+ T cells and on T helper cells (CD3+CD4+) (data not 
shown). 
 
CCR6  
 
Regarding to the analysis of CCR6, there were no significant differences in CCR6 MFI 
values on total CD3+ T cells and on T helper cells (CD3+CD4+) (data not shown). 
 
CXCR3  
 
Respectively to the CXCR3 expression, there were no significant differences in CXCR3 
MFI values on total CD3+ T cells and on T helper cells (CD3+CD4+) (data not shown). 
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3.2.4. B CELLS  
 
 
 Effect of celastrol on B cell subpopulations 
 
 
Total CD19+ B cells and B cell subpopulations 
 
The analysis of the frequency of total CD19+ B cells has revealed that no statistically 
significant differences were found between the tested conditions in chronic RA patients 
(data not shown). Additionally, there were no significant differences in the levels of the B 
cell subpopulations (naïve, pre-switch memory, post-switch memory, double-negative B 
cells and transitional B cells, plasmablasts) in all conditions (data not shown). 
 
 
 
 
 Effect of celastrol on B cell markers 
 
 
BAFF-R  
 
We have observed that no significant differences exist in the frequency of BAFF-R+ 
cells and in BAFF-R MFI values on total CD19+ B cells and in all B cell subpopulations, in 
all tested conditions (data not shown). 
 
FcgRIIB  
 
Regarding to the analysis of FcgRIIB, no significant differences were found in FcgRIIB 
MFI values on total CD19+ B cells and all B cell subpopulations analyzed (data not shown). 
 
CD38  
 
The analysis of the expression of CD38 has revelead that no significant differences were 
observed in CD38 MFI values on total CD19+ B cells and all B cell subpopulations 
analyzed (data not shown). 
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CD21  
 
Respectively to the CD21 expression, there were no significant differences in the levels 
of CD21+ cells and in CD21 MFI values on total CD19+ B cells and all B cell 
subpopulations analyzed (data not shown). 
 
CD21lowCD38low 
 
Concerning to the expression of CD21lowCD38low, there were no significant differences 
in the levels of CD21lowCD38low+ cells on total CD19+ B cells (data not shown).  
 
HLA-DR 
 
The analysis of HLA-DR has revelead that no significant differences were observed in 
the levels of HLA-DR+ cells and in HLA-DR MFI values on total CD19+ B cells and all B 
cell subpopulations analyzed (data not shown). 
 
RANKL 
 
Regarding to the analysis of RANKL, there were no significant differences in the levels 
of RANKL+ cells and in RANKL MFI values on total CD19+ B cells and all B cell 
subpopulations analyzed (data not shown). 
 
CD95 
 
Respectively to the CD95 expression, there were no significant differences in the levels 
of CD95+ cells and in CD95 MFI values on total CD19+ B cells and all B cell 
subpopulations analyzed (data not shown).  
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3.3. CHRONIC RA PATIENTS vs HEALTHY CONTROLS 
 
3.3.1. MONOCYTES  
 
 
 Effect of celastrol on monocyte population 
 
 
Total CD14+ cells 
 
The analysis of the frequency of total CD14+ cells has revealed that statistically 
significant differences were found, when comparing chronic RA patients with healthy 
controls. 
Specifically, it was observed that leukocytes from chronic RA patients tested with LPS 
(p=0.0173) condition had a significantly increased frequency of total CD14+ cells, and when 
tested with Celastrol (p=0.0290), had a significantly reduced frequency in comparison to 
healthy controls (Figure 27). A linear downward trend is observed in Media + Ethanol, 
Celastrol and Celastrol + LPS conditions, which leads us to assume that the significant 
difference observed in Celastrol is due to the disease phenotype and not to the effect of the 
compound. However, the significant difference observed in LPS condition seems to indicate 
that the LPS addition reduces the frequency of total CD14+ cells in healthy controls. 
  
 
 
 
 
 
 
 
Figure 27 – Frequency of CD14+ cells in chronic RA patients tested with LPS is significantly 
increased in comparison to healthy controls, and tested with Celastrol is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood monocytes 
from chronic RA patients and healthy controls tested with several conditions. Data are expressed 
as median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
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 Effect of celastrol on monocyte markers 
 
 
CD16 
 
Regarding to CD16, it was observed that no significant differences were observed in the 
levels of CD16+ cells and in CD16 MFI values on total CD14+ cells, when comparing 
chronic RA patients with healthy controls (data not shown).  
 
CD86  
 
The analysis of CD86 has revelead that significant differences were observed in the 
levels of CD86+ cells and in CD86 MFI values on total CD14+ cells, when comparing 
chronic RA patients with healthy controls.  
Specifically, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0007), Celastrol (p=0.0185) and Celastrol + LPS (p=0.0007) conditions, had 
significantly reduced frequencies of CD86+ cells on total CD14+ cells in comparison to 
healthy controls (Figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 – Frequency of CD86+ cells in chronic RA patients tested with Media + Ethanol, Celastrol 
and Celastrol + LPS is significantly reduced in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood monocytes from chronic RA patients and healthy controls 
tested with several conditions. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Also, it was observed that leukocytes from chronic RA patients tested with Media + 
Ethanol (p=0.0007), Celastrol (p=0.0070) and Celastrol + LPS (p=0.0007) conditions, had 
significantly reduced expression of CD86 MFI values on total CD14+ cells in comparison to 
healthy controls (Figure 29). 
Both in the levels of CD86+ cells and in CD86 MFI values on total CD14+ cells, a linear 
downward trend is observed in Media + Ethanol and Celastrol conditions, which leads us to 
assume that the significant differences observed in these conditions are due to the disease 
phenotype and not to the effect of the compound. However, the significant difference 
observed in Celastrol + LPS condition seems to indicate that the LPS addition reduces the 
levels of CD86+ cells on total CD14+ cells in chronic RA patients and reduces the CD86 
MFI values on total CD14+ cells in healthy controls. 
 
 
 
 
 
 
 
 
 
 
 
HLA-DR  
 
Respectively to the HLA-DR expression, there were no significant differences in the 
levels of HLA-DR+ cells on total CD14+ cells, when comparing chronic RA patients with 
healthy controls (data not shown). 
However, significant differences were found in HLA-DR MFI values on total CD14+ 
cells, when comparing chronic RA patients with healthy controls. It was observed that 
Figure 29 – Expression of CD86 (MFI) cell marker on CD14+ cells in chronic RA patients tested with 
Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy controls. 
Data from flow cytometry analysis of peripheral blood monocytes from chronic RA patients and healthy 
controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
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leukocytes from chronic RA patients tested with Media + Ethanol (p=0.0047), Celastrol 
(p=0.0016) and Celastrol + LPS (p=0.0127) conditions, had significantly reduced expression 
of HLA-DR MFI values on total CD14+ cells in comparison to healthy controls (Figure 30). 
A linear downward trend is observed in Media + Ethanol, Celastrol and Celastrol + LPS 
conditions, which leads us to assume that the significant differences observed in these 
conditions are due to the disease phenotype and not to the effect of the added stimuli. 
However, the LPS condition seems to indicate that the LPS addition increases the HLA-DR 
MFI values on total CD14+ cells both in healthy controls and in chronic RA patients. 
  
 
 
 
 
 
 
 
 
 
CD115  
 
Concerning to the expression of CD115, no significant differences were found in the 
levels of CD115+ cells and in CD115 MFI values on total CD14+ cells, when comparing 
chronic RA patients with healthy controls (data not shown).  
 
RANK 
 
The analysis of the expression of RANK has revelead that no significant differences 
were observed in the levels of RANK+ cells and in RANK MFI values on total CD14+ cells, 
when comparing chronic RA patients with healthy controls (data not shown). 
Figure 30 – Expression of HLA-DR (MFI) cell marker on CD14+ cells in chronic RA patients tested with 
Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy controls. 
Data from flow cytometry analysis of peripheral blood monocytes from chronic RA patients and healthy 
controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
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3.3.2. GRANULOCYTES  
 
 
 Effect of celastrol on granulocyte population 
 
 
Total CD66b+ cells 
 
The analysis of the frequency of total CD66b+ cells has revealed that leukocytes from 
chronic RA patients tested with Celastrol (p=0.0133) and Celastrol + LPS (p=0.0376) 
conditions, had significantly increased frequencies of total CD66b+ cells in comparison to 
healthy controls (Figure 31). An increasing linear trend is observed in all tested conditions, 
which leads us to assume that the significant differences observed are due to the disease 
phenotype and not to the effect of the added stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31 – Frequency of total CD66b+ cells in chronic RA patients tested with Celastrol and 
Celastrol + LPS is significantly increased in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood granulocytes cells from chronic RA patients and healthy 
controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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 Effect of celastrol on granulocyte markers 
 
 
CD11b  
 
Regarding to the analysis of CD11b, no significant differences were observed in the 
levels of CD11b+ cells and in CD11b MFI values on total CD66b+ cells, when comparing 
chronic RA patients with healthy controls (data not shown). 
 
 
CD15 
 
The analysis of the expression of CD15 has revelead that leukocytes from chronic RA 
patients tested with Celastrol (p=0.0043) condition, had significantly increased frequencies 
of CD15+ cells on total CD66b+ cells in comparison to healthy controls (Figure 32). An 
increasing linear trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli. 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, no significant differences were found in CD15 MFI values on total 
CD66b+ cells, when comparing chronic RA patients with healthy controls (data not shown). 
Figure 32 – Frequency of CD15+ cells on total CD66b+ cells in chronic RA patients tested with 
Celastrol is significantly increased in comparison to healthy controls. Data from flow cytometry 
analysis of peripheral blood granulocytes cells from chronic RA patients and healthy controls 
tested with several conditions. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
68 
 
CD16 
 
Respectively to the CD16 expression, there were significant differences in the levels of 
CD16high cells and CD16low cells on total CD66b+ cells, when comparing chronic RA 
patients with healthy controls. 
Specifically, it was revelead that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0420) and Celastrol + LPS (p=0.0290) conditions, had significantly 
increased frequencies of CD16high cells on total CD66b+ cells in comparison to healthy 
controls (Figure 33).  
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, with Celastrol + LPS (p=0.0080) condition, it was observed a significantly 
reduced frequency of CD16low cells on total CD66b+ cells in comparison to healthy controls 
(Figure 34). 
Both in the levels of CD16high cells and CD16low cells on total CD66b+ cells, a linear 
downward and increasing trend, respectively, is observed in Media + Ethanol, Celastrol and 
Celastrol + LPS conditions, which leads us to assume that the significant difference 
observed in Celastrol + LPS condition is due to the disease phenotype and not to the effect 
of the added stimuli. However, the LPS condition seems to indicate that the LPS addition 
Figure 33 – Frequency of CD16high cells on total CD66b+ cells in chronic RA patients tested with 
Media + Ethanol and Celastrol + LPS is significantly increased in comparison to healthy controls. 
Data from flow cytometry analysis of peripheral blood granulocytes cells from chronic RA patients 
and healthy controls tested with several conditions. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
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increases the levels of CD16high cells on total CD66b+ cells and reduces the levels of 
CD16low cells on total CD66b+ cells in healthy controls. 
 
 
 
 
 
 
 
 
 
 
 
However, no significant differences were found in CD16high MFI values, CD16low MFI 
values and CD16 MFI values on total CD66b+ cells, when comparing chronic RA patients 
with healthy controls (data not shown). 
 
CD62L 
 
Regarding to the analysis of CD62L, it was observed that leukocytes from chronic RA 
patients tested with Media + Ethanol (p=0.0013), Celastrol (p=0.0120) and Celastrol + LPS 
(p=0.0027) conditions, had significantly reduced expression of CD62L MFI values on total 
CD66b+ cells in comparison to healthy controls (Figure 35). The levels of CD62L cells are 
reduced in chronic RA patients, and as they are pre-primed they respond more when 
addeding LPS, then no significant difference was observed in this condition. 
 
Figure 34 – Frequency of CD16low cells on total CD66b+ cells in chronic RA patients tested with 
Celastrol + LPS is significantly reduced in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood granulocytes cells from chronic RA patients and healthy 
controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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CXCR2 
 
Respectively to the CXCR2 expression, there were significant differences in the levels of 
CXCR2+ cells and in CXCR2 MFI values on total CD66b+ cells, when comparing chronic 
RA patients with healthy controls (data not shown). CORRECTO  
Specifically, it was observed that leukocytes from chronic RA patients tested with 
Celastrol + LPS (p=0.0115) condition, had a significantly increased frequency of CXCR2+ 
cells on total CD66b+ cells in comparison to healthy controls (Figure 36). 
Figure 35 – Expression of CD62L (MFI) cell marker on CD66b+ cells on chronic RA patients tested 
with Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy 
controls. Data from flow cytometry analysis of peripheral blood granulocytes cells from healthy 
controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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When tested with Media + Ethanol (p=0.0193) and Celastrol (p=0.0280) conditions, had 
significantly increased expression of CXCR2 MFI values on total CD66b+ cells in 
comparison to healthy controls (Figure 37).  
Both in the levels of CXCR2+ cells and in MFI values, a increasing linear trend is 
observed in all condition, except LPS. It was observed that LPS seems to decrease the 
CXCR2 expression in chronic RA patients. 
 
 
 
 
 
 
 
 
Figure 36 – Frequency of CXCR2+ cells on total CD66b+ cells in chronic RA patients tested with 
Celastrol + LPS is significantly increased in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood granulocytes cells from chronic RA patients and healthy 
controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Figure 37 – Expression of CXCR2 (MFI) cell marker on CD66b+ cells on chronic RA patients tested 
with Media + Ethanol and Celastrol is significantly increased in comparison to healthy controls. Data 
from flow cytometry analysis of peripheral blood granulocytes cells from healthy controls tested 
with several conditions. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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3.3.3. T CELLS  
 
 
 Effect of celastrol on T cell subpopulations 
 
 
Total CD3+ T cells and the main T cell subpopulations (CD4+ and CD8+) 
 
The analysis of the frequency of total CD3+ T cells has revealed that no statistically 
significant differences were found, when comparing chronic RA patients with healthy 
controls (data not shown). Additionally, there were no significant differences in the levels of 
the main T cell subpopulations (T helper cells (CD3+CD4+) and T cytotoxic cells 
(CD3+CD8+)), when comparing chronic RA patients with healthy controls (data not 
shown). 
 
T helper cell subpopulations (CD3+CD4+) 
 
Regarding to the analysis of the T helper (CD3+CD4+) cell subpopulations, no 
significant differences were found in the frequency of the cell subpopulations analyzed 
based on the CD45RO and HLA-DR expression, when comparing chronic RA patients with 
healthy controls (data not shown), except in naïve activated (CD45RO-HLA-DR+) T cells.  
Specifically, it was observed that leukocytes from chronic RA patients tested with 
Celastrol (p=0.0010) condition, had a significantly increased frequency of naïve activated T 
cells (CD45RO-HLA-DR+) in comparison to healthy controls (Appendix III.6). An 
increasing linear trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli.  
According to the CD25 and Foxp3 expression, there were no significant differences in 
the levels of the regulatory T (Treg) cells (CD25+Foxp3+ subset), when comparing chronic 
RA patient with healthy controls (data not shown). 
Additionally, no significant differences were found in the levels of CD25 subpopulations 
of regulatory T (Treg) cells), when comparing chronic RA patients with healthy controls 
(data not shown), except in CD25bright regulatory T (Treg) cells. 
Specifically, it was observed that leukocytes from chronic RA patients tested with 
Celastrol (p=0.0186) condition, had a significantly increased frequency of CD25bright 
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regulatory T (Treg) cells (CD4+CD25bright) in comparison to healthy controls (Appendix 
III.7). An increasing linear downward is observed in all tested conditions, which leads us to 
assume that the significant differences observed are due to the disease phenotype and not to 
the effect of the added stimuli. 
Furthermore, there were no significant differences in the levels of the T helper cell 
subpopulations based on the CD45RO and CCR7 expression, when comparing chronic RA 
patients with healthy controls (data not shown), except in effector memory T cells 
(CD45RO+CCR7-). 
Specifically, it was observed that leukocytes from chronic RA patients tested with 
Media + Ethanol (p=0.0393) and Celastrol (p=0.0280) conditions, had significantly reduced 
frequencies of effector memory T cells in comparison to healthy controls (Appendix III.8). 
A linear downward trend is observed in all tested conditions, which leads us to assume that 
the significant differences observed are due to the disease phenotype and not to the effect of 
the added stimuli.  
Additionaly, significant differences were found in the levels of central memory and 
effector memory T cell subpopulations, when comparing chronic RA patients with healthy 
controls, except in central memory Th17-like cells (CD45RO+CCR7+CXCR3-CCR6+) 
(data not shown).  
Specifically, regarding to the central memory (CD45RO+CCR7+) T cell 
subpopulations, it was observed that leukocytes from chronic RA patients tested with 
Celastrol (p=0.0260) and Celastrol + LPS (p=0.0080) conditions, had significantly increased 
frequencies of Th1-like cells (CXCR3+CCR6-) in comparison to healthy controls 
(Appendix III.9). An increasing linear trend is observed in all tested conditions, which leads 
us to assume that the significant differences observed are due to the disease phenotype and 
not to the effect of the added stimuli. When tested with Media + Ethanol (p=0.0020), LPS 
(p=0.0043), Celastrol (p=0.0005) and Celastrol + LPS (p=0.0007) conditions, it was 
observed significantly reduced frequencies of Th2-like cells (CXCR3-CCR6-) in 
comparison to healthy controls (Appendix III.10). A linear downward trend is observed in 
all tested conditions, which leads us to assume that the significant differences observed are 
due to the disease phenotype and not to the effect of the added stimuli.  
Regarding to the effector memory (CD45RO+CCR7-) T cell subpopulations, it was 
observed that leukocytes from chronic RA patients tested with LPS (p=0.0303), Celastrol 
(p=0.0047) and Celastrol + LPS (p=0.0023) conditions, had significantly increased 
frequencies of Th1-like cells (CXCR3+CCR6-) in comparison to healthy controls 
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(Appendix III.11). An increasing linear trend is observed in all tested conditions, which 
leads us to assume that the significant differences observed are due to the disease phenotype 
and not to the effect of the added stimuli. When tested with Celastrol + LPS (p=0.0047) 
condition, it was observed a significantly reduced frequency of Th2-like cells (CXCR3-
CCR6-) in comparison to healthy controls (Appendix III.12). A linear downward trend is 
observed in all tested conditions, which leads us to assume that the significant differences 
observed are due to the disease phenotype and not to the effect of the added stimuli. When 
tested with Media + Ethanol (p=0.0206), LPS (p=0.0087), Celastrol (p=0.0047) and 
Celastrol + LPS (p=0.0080) conditions, it was observed significantly reduced frequencies of 
Th17-like cells (CXCR3-CCR6+) in comparison to healthy controls (Appendix III.13). 
Once again, a linear downward trend is observed in all tested conditions, which leads us to 
assume that the significant differences observed are due to the disease phenotype and not to 
the effect of the added stimuli.  
 
T cytotoxic cell subpopulations (CD3+CD8+) 
 
Regarding to the analysis of the T cytotoxic (CD3+CD8+) cell subpopulations, no 
significant differences were found in the frequency of the cell subpopulations analyzed 
(naïve (CD45RO-HLA-DR-), naïve activated (CD45RO-HLA-DR+), memory 
(CD45RO+HLA-DR-) and memory activated (CD45RO+HLA-DR+) T cytotoxic cells), 
when comparing chronic RA patients with healthy controls (data not shown). 
 
 
 
 
 
 Effect of celastrol on T cell markers 
 
 
HLA-DR  
 
Regarding to the analysis of HLA-DR, significant differences were found in HLA-DR 
MFI values on total CD3+ T cells and the main T cell subpopulations (T helper cells 
(CD3+CD4+) and T cytotoxic cells (CD3+CD8+)) analyzed, when comparing chronic RA 
patients with healthy controls.  
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Specifically, it was observed that leukocytes from chronic RA patients tested with 
Media + Ethanol (p=0.0043), LPS (p=0.0173),  Celastrol (p=0.0030) and Celastrol + LPS 
(p=0.0047) conditions, had significantly increased expression of HLA-DR MFI cell marker 
on total CD3+ T cells in comparison to healthy controls (Figure 38). An increasing linear 
trend is observed in all tested conditions, which leads us to assume that the significant 
differences observed are due to the disease phenotype and not to the effect of the added 
stimuli.   
 
 
 
 
 
 
 
 
 
 
 
Also, when tested with Media + Ethanol (p=0.0013), LPS (p=0.0087), Celastrol (p=0.0013) 
and Celastrol + LPS (p=0.0027) conditions, had significantly increased expression of HLA-
DR MFI cell marker on T helper cells (CD3+CD4+) in comparison to healthy controls 
(Appendix III.14). Once again, an increasing linear trend is observed in all tested 
conditions, which leads us to assume that the significant differences observed are due to the 
disease phenotype and not to the effect of the added stimuli. With Media + Ethanol 
(p=0.0120), Celastrol (p=0.0040) and Celastrol + LPS (p=0.0275) conditions, it was 
observed a significantly increased expression of HLA-DR MFI cell marker on T cytotoxic 
cells (CD3+CD8+) in comparison to healthy controls (Appendix III.15). Once again, an 
increasing linear trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli.  
Figure 38 – Expression of HLA-DR (MFI) cell marker on total CD3+ T cells in chronic RA patients tested 
with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly increased in comparison to 
healthy controls. Data from flow cytometry analysis of peripheral blood T cells from chronic RA patients 
and healthy controls tested with several conditions. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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CD40L  
 
The analysis of the expression of CD40L has revelead that no significant differences 
were observed in CD40L MFI values on total CD3+ T cells and the main T cell 
subpopulations (T helper cells and T cytotoxic cells) analyzed, when comparing chronic RA 
patients with healthy controls (data not shown).  
 
RORgT  
 
Respectively to the RORgT expression, it was observed that leukocytes from chronic RA 
patients tested with Celastrol (p=0.0062) and Celastrol + LPS (p=0.0124) conditions, had 
significantly increased expression of RORgT MFI cell marker on T helper cells 
(CD3+CD4+) in comparison to healthy controls (Appendix III.16). An increasing linear 
trend is observed in all tested conditions, which leads us to assume that the significant 
differences observed are due to the disease phenotype and not to the effect of the added 
stimuli.   
 
Foxp3  
 
Concerning to the expression of Foxp3, there were significant differences in Foxp3 MFI 
values on regulatory T (Treg) cells (CD25+Foxp3+ subset) and on CD25 subpopulations of 
regulatory T (Treg) cells (except in CD25dim Treg cells (data not shown)), when comparing 
chronic RA patients with healthy controls. 
Particularly, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0295), Celastrol (p=0.0186) and Celastrol + LPS (p=0.0451) conditions, had 
significantly reduced expression of Foxp3 MFI cell marker on regulatory T (Treg) cells 
(CD25+Foxp3+ subset) in comparison to healthy controls (Appendix III.17). A linear 
downward trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli.   
In addition, when tested with Media + Ethanol (p=0.0451), Celastrol (p=0.0451) and 
Celastrol + LPS (p=0.0295) conditions, it was observed a significantly reduced expression 
of Foxp3 MFI cell marker on CD25int Treg cells (CD4+CD25int) in comparison to healthy 
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controls (Appendix III.18). An increasing linear trend is observed in all tested conditions, 
which leads us to assume that the significant differences observed are due to the disease 
phenotype and not to the effect of the added stimuli. 
With Media + Ethanol (p=0.0109), LPS (p=0.0455),  Celastrol (p=0.0272) and Celastrol 
+ LPS (p=0.0295) conditions, it was observed a significantly reduced expression of Foxp3 
MFI cell marker on CD25bright Treg cells (CD4+CD25bright) in comparison to healthy 
controls (Appendix III.19). A linear downward trend is observed in all tested conditions, 
which leads us to assume that the significant differences observed are due to the disease 
phenotype and not to the effect of the added stimuli. 
 
CCR7  
 
The analysis of CCR7 has revelead that no significant differences were observed in 
CCR7 MFI values on total CD3+ T cells and on T helper cells (CD3+CD4+), when 
comparing chronic RA patients with healthy controls (data not shown). 
 
CCR6  
 
Regarding to the analysis of CCR6, there were no significant differences in CCR6 MFI 
values on total CD3+ T cells and on T helper cells (CD3+CD4+), when comparing chronic 
RA patients with healthy controls (data not shown). 
 
 
CXCR3  
 
Respectively to the CXCR3 expression, there were significant differences in CXCR3 
MFI values on total CD3+ T cells and on T helper cells (CD3+CD4+), when comparing 
chronic RA patients with healthy controls. 
Specifically, it was observed that leukocytes from chronic RA patients tested with 
Celastrol + LPS (p=0.0077) condition, had a significantly increased expression of CXCR3 
MFI cell marker on total CD3+ T cells in comparison to healthy controls (Figure 39).   
78 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, when tested with Media + Ethanol (p=0.0260), LPS (p=0.0303), Celastrol 
(p=0.0080) and Celastrol + LPS (p=0.0030) conditions, it was observed a significantly 
increased expression of CXCR3 MFI cell marker on T helper cells (CD3+CD4+) in 
comparison to healthy controls (Appendix III.20).  
An increasing linear trend is observed in all tested conditions, which leads us to assume 
that the significant differences observed are due to the disease phenotype and not to the 
effect of the added stimuli. 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 – Expression of CXCR3 (MFI) cell marker on total CD3+ T cells in chronic RA patients tested 
with Celastrol + LPS is significantly increased in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood T cells from chronic RA patients and healthy controls tested with 
several conditions. Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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3.3.4. B CELLS  
 
 
 Effect of celastrol on B cell subpopulations 
 
 
Total CD19+ B cells and B cell subpopulations  
 
The analysis of the frequency of total CD19+ B cells has revealed that leukocytes from 
chronic RA patients tested with Media + Ethanol (p=0.0027), Celastrol (p=0.0127) and 
Celastrol + LPS (p=0.0080) conditions, had significantly reduced frequencies of total 
CD19+ B cells in comparison to healthy controls (Figure 40). However, since a downward 
trend seems to be linear in all tested conditions in chronic RA patients, there being a 
decrease of CD19+ B cell levels in all conditions, we assume that the significant differences 
observed are due to the disease phenotype and not to the effect of the added stimuli.  
 
 
Additionally, there were no significant differences in the levels of the B cell 
subpopulations (naïve, pre-switch memory, post-switch memory, double-negative B cells 
and plasmablasts), when comparing chronic RA patients with healthy controls (data not 
shown), except in transitional B cells (IgD+CD38++). Herein, it was observed that 
leukocytes from chronic RA patients tested with LPS (p=0.0173), Celastrol (p=0.0193) and 
Figure 40 – Frequency of total CD19+ B cells in chronic RA patients tested with Media + Ethanol, 
Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy controls. Data from 
flow cytometry analysis of peripheral blood B cells from chronic RA patients and healthy controls 
tested with several conditions. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Celastrol + LPS (p=0.0280) conditions, had significantly reduced frequencies of transitional 
B cells in comparison to healthy controls (Appendix IV.14). Once again, a linear downward 
trend is observed in all tested conditions, which leads us to assume that the significant 
differences observed are due to the disease phenotype and not to the effect of the added 
stimuli. 
 
 
 
 Effect of celastrol on B cell markers 
 
 
BAFF-R  
 
The analysis of the frequency of BAFF-R+ cells on total CD19+ B cells has revealed that 
statistically significant differences were found, when comparing chronic RA patients with 
healthy controls. However, there were no significant differences in the levels of BAFF-R+ 
cells in all B cell subpopulations (except in pre-switch memory B cells) analyzed, when 
comparing chronic RA patients with healthy controls (data not shown).  
Specifically, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0007) and Celastrol + LPS (p=0.0080) conditions, had significantly reduced 
frequencies of BAFF-R+ cells on total CD19+ B cells in comparison to healthy controls 
(Figure 41). A linear downward trend is observed in all tested conditions, which leads us to 
assume that the significant differences observed are due to the disease phenotype and not to 
the effect of the added stimuli. 
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Similarly, when tested with Media + Ethanol (p=0.0020), LPS (p=0.0317), Celastrol 
(p=0.0113) and Celastrol + LPS (p=0.0210) conditions, had significantly reduced 
frequencies of BAFF-R+ cells on pre-switch memory (IgD+CD27+) B cells in comparison 
to healthy controls (Appendix IV.15). Once again, a linear downward trend is observed in 
all tested conditions, which leads us to assume that the significant differences observed are 
due to the disease phenotype and not to the effect of the added stimuli.  
Furthermore, significant differences were found in BAFF-R MFI values on total CD19+ 
B cells and all B cell subpopulations analyzed, when comparing chronic RA patients with 
healthy controls.  
Particularly, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0027), LPS (p=0.0173), Celastrol (p=0.0027) and Celastrol + LPS 
(p=0.0027) conditions, had significantly reduced expression of BAFF-R MFI cell marker on 
total CD19+ B cells in comparison to healthy controls (Figure 42). A linear downward trend 
is observed in all tested conditions, which leads us to assume that the significant differences 
observed are due to the disease phenotype and not to the effect of the added stimuli.  
Figure 41 – Frequency of BAFF-R+ cells on total CD19+ B cells in chronic RA patients tested with 
Media + Ethanol and Celastrol + LPS is significantly reduced in comparison to healthy controls. 
Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients and 
healthy controls tested with several conditions. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
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Similarly, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0013), LPS (p=0.0173), Celastrol (p=0.0027) and Celastrol + LPS 
(p=0.0013) conditions, had significantly reduced expression of BAFF-R MFI cell marker on 
naïve B cells (IgD+CD27-) in comparison to healthy controls (Appendix IV.16). Once 
again, a linear downward trend is observed in all tested conditions, which leads us to assume 
that the significant differences observed are due to the disease phenotype and not to the 
effect of the added stimuli. Also, when tested with Media + Ethanol (p=0.0047), LPS 
(p=0.0159), Celastrol (p=0.0070) and Celastrol + LPS (p=0.0020) conditions, had 
significantly reduced expression of BAFF-R MFI cell marker on pre-switch memory 
(IgD+CD27+) B cells in comparison to healthy controls (Appendix IV.17). Once again, a 
linear downward trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli. With Media + Ethanol (p=0.0127), LPS (p=0.0317), Celastrol (p=0.0070) and 
Celastrol + LPS (p=0.0120) conditions, it was observed a significantly reduced expression 
of BAFF-R MFI cell marker on post-switch memory (IgD-CD27+) B cells in comparison to 
healthy controls (Appendix IV.18). Once again, a linear downward trend is observed in all 
tested conditions, which leads us to assume that the significant differences observed are due 
to the disease phenotype and not to the effect of the added stimuli. With Media + Ethanol 
Figure 42 – Expression of BAFF-R (MFI) cell marker on total CD19+ B cells in chronic RA patients tested 
with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy 
controls. Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients and 
healthy controls tested with several conditions. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
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(p=0.0047), LPS (p=0.0079) and Celastrol + LPS (p=0.0120) conditions, it was observed a 
significantly reduced expression of BAFF-R MFI cell marker on double-negative (IgD-
CD27-) B cells in comparison to healthy controls (Appendix IV.19). Once again, a linear 
downward trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli. 
 
FcgRIIB  
 
Regarding to the analysis of FcgRIIB, no significant differences were found in FcgRIIB 
MFI values on total CD19+ B cells and all B cell subpopulations analyzed, when comparing 
chronic RA patients with healthy controls (data not shown).  
 
CD38 
 
The analysis of the expression of CD38 has revelead that no significant differences were 
observed in CD38 MFI values on total CD19+ B cells and all B cell subpopulations 
analyzed (except in post-switch memory and double-negative B cells), in all tested 
conditions, when comparing chronic RA patients with healthy controls (data not shown). 
However, it was observed that leukocytes from chronic RA patients tested with LPS 
(p=0.0303) and Celastrol (p=0.0183) conditions, had significantly reduced expression of 
CD38 MFI cell marker on post-switch memory (IgD-CD27+) B cells, in comparison to 
healthy controls (Appendix IV.20); and when tested with Media + Ethanol (p=0.0047), LPS 
(p=0.0173), Celastrol (p=0.0027) and Celastrol + LPS (p=0.0040) conditions, had 
significantly reduced expression of CD38 MFI cell marker on double-negative (IgD-CD27-) 
B cells, in comparison to healthy controls (Appendix IV.21). A linear downward trend is 
observed in all tested conditions of post-switch memory and double-negative B cells, which 
leads us to assume that the significant differences observed are due to the disease phenotype 
and not to the effect of the added stimuli.  
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CD21  
 
Respectively to the CD21 expression, it was revealed that statistically significant 
differences were found in the levels of CD21+ cells on total CD19+ B cells and all B cell 
subpopulations (except in post-switch memory B cells), when comparing chronic RA 
patients with healthy controls. Specifically, it was observed that leukocytes from chronic RA 
patients tested with Media + Ethanol (p=0.0010), LPS (p=0.0303), Celastrol (p=0.0053) and 
Celastrol + LPS (p=0.0127) conditions, had significantly reduced frequencies of CD21+ 
cells on total CD19+ B cells in comparison to healthy controls (Figure 43). A linear 
downward trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
Similarly, it was observed that leukocytes from chronic RA patients tested with Media + 
Ethanol (p=0.0097), Celastrol (p=0.0436) and Celastrol + LPS (p=0.0117) conditions, had 
significantly reduced frequencies of CD21+ cells on naïve B cells (IgD+CD27-) in 
comparison to healthy controls (Appendix IV.22). Once again, a linear downward trend is 
observed in all tested conditions, which leads us to assume that the significant differences 
Figure 43 – Frequency of CD21+ cells on total CD19+ B cells in chronic RA patients tested with 
Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in comparison to 
healthy controls. Data from flow cytometry analysis of peripheral blood B cells from chronic RA 
patients and healthy controls tested with several conditions. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
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observed are due to the disease phenotype and not to the effect of the added stimuli. Also, 
when tested with Media + Ethanol (p=0.0023), LPS (p=0.0159), Celastrol (p=0.0013) and 
Celastrol + LPS (p=0.0010) conditions, had significantly reduced frequencies of CD21+ 
cells on pre-switch memory (IgD+CD27+) B cells in comparison to healthy controls 
(Appendix IV.23). Once again, a linear downward trend is observed in all tested conditions, 
which leads us to assume that the significant differences observed are due to the disease 
phenotype and not to the effect of the added stimuli.  
Furthermore, no significant differences were found in CD21 MFI values on total CD19+ 
B cells and all B cell subpopulations (except in pre-switch memory B cells) analyzed, when 
comparing chronic RA patients with healthy controls.  
Particularly, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0047), LPS (p=0.0079), Celastrol (p=0.0007) and Celastrol + LPS 
(p=0.0007) conditions, had significantly reduced expression of CD21 MFI cell marker on 
pre-switch memory B cells (IgD+CD27+) in comparison to healthy controls (Appendix 
IV.24). A linear downward trend is observed in all tested conditions, which leads us to 
assume that the significant differences observed are due to the disease phenotype and not to 
the effect of the added stimuli.  
 
CD21lowCD38low 
 
Concerning to the expression of CD21lowCD38low, it was observed that leukocytes from 
chronic RA patients tested with Media + Ethanol (p=0.0007), LPS (p=0.0317), Celastrol 
(p=0.0013) and Celastrol + LPS (p=0.0047) conditions, had significantly increased 
frequencies of CD21lowCD38low+ cells on total CD19+ B cells in comparison to healthy 
controls (Figure 44). An increasing linear trend is observed in all tested conditions, which 
leads us to assume that the significant differences observed are due to the disease phenotype 
and not to the effect of the added stimuli.  
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HLA-DR 
 
The analysis of the expression of HLA-DR has revelead that statistically significant 
differences were found in the levels of HLA-DR+ cells on total CD19+ B cells and all B cell 
subpopulations (except in naïve B), when comparing chronic RA patients with healthy 
controls. 
Specifically, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0137), Celastrol (p=0.0007) and Celastrol + LPS (p=0.0013) conditions, had 
significantly reduced frequencies of HLA-DR+ cells on total CD19+ B cells in comparison 
to healthy controls (Figure 45). A linear downward trend is observed in all tested 
conditions, which leads us to assume that the significant differences observed are due to the 
disease phenotype and not to the effect of the added stimuli. 
Figure 44 – Frequency of CD21lowCD38low+ cells on total CD19+ B cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly increased in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood B cells from 
chronic RA patients and healthy controls tested with several conditions. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
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Similarly, it was observed that leukocytes from chronic RA patients tested with Media + 
Ethanol (p=0.0050), LPS (p=0.0238) and Celastrol + LPS (p=0.0007) conditions, had 
significantly reduced frequencies of HLA-DR+ cells on pre-switch memory B cells 
(IgD+CD27+) in comparison to healthy controls (Appendix IV.25). Once again, a linear 
downward trend is observed in all tested conditions, which leads us to assume that the 
significant differences observed are due to the disease phenotype and not to the effect of the 
added stimuli. Also, when tested with Celastrol (p=0.0483) condition, had significantly 
reduced frequency of HLA-DR+ cells on post-switch memory B cells (IgD-CD27+) in 
comparison to healthy controls (Appendix IV.26). Once again, a linear downward trend is 
observed in all tested conditions, which leads us to assume that the significant differences 
observed are due to the disease phenotype and not to the effect of the added stimuli. 
Furthermore, no significant differences were found in HLA-DR MFI values on total 
CD19+ B cells and all B cell subpopulations analyzed, when comparing chronic RA patients 
with healthy controls.  
 
 
 
Figure 45 – Frequency of HLA-DR+ cells on total CD19+ B cells in chronic RA patients tested with 
Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy 
controls. Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients 
and healthy controls tested with several conditions. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
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RANKL 
 
Regarding to the analysis of RANKL, there were no significant differences in the levels 
of RANKL+ cells on total CD19+ B cells, when comparing chronic RA patients with 
healthy controls (data not shown). However, it was revealed that statistically significant 
differences were found in the levels of RANKL+ cells on all B cell subpopulations (except 
in naïve B cells and pre-switch memory B) analyzed, when comparing chronic RA patients 
with healthy controls. 
Specifically, it was observed that leukocytes from chronic RA patients tested with 
Celastrol (p=0.0025) condition, had significantly increased frequency of RANKL+ cells on 
post-switch memory B cells (IgD-CD27+) in comparison to healthy controls (Appendix 
IV.27). Also, with Celastrol (p=0.0485) condition, it was observed a significantly increased 
frequency of RANKL+ cells on double-negative B cells (IgD-CD27-) in comparison to 
healthy controls (Appendix IV.28). 
Both in the frequencies of RANKL+ on post-switch memory B cells (IgD-CD27+) and 
on double-negative B cells (IgD-CD27-), an increasing linear trend is observed, but celastrol 
seems indicate that reduces the frequencies of these subpopulations in healthy controls.  
Furthermore, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0109) and Celastrol + LPS (p=0.0420) conditions, had significantly reduced  
expression of RANKL MFI values on total CD19+ B cells in comparison to healthy controls 
(Figure 46). A linear downward trend is observed in all tested conditions, which leads us to 
assume that the significant differences observed are due to the disease phenotype and not to 
the effect of the added stimuli.   
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However, no significant differences were found in RANKL MFI values on all B cell 
subpopulations (except in naïve B cells) analyzed, when comparing chronic RA patients 
with healthy controls (data not shown).  
Specifically, it was observed that leukocytes from chronic RA patients tested with Media 
+ Ethanol (p=0.0031), Celastrol (p=0.0186),  Celastrol + LPS (p=0.0120) conditions, had 
significantly reduced expression of RANKL MFI values on naïve B cells (IgD+CD27-) in 
comparison to healthy controls (Appendix IV.29). A linear downward trend is observed in 
all tested conditions, which leads us to assume that the significant differences observed are 
due to the disease phenotype and not to the effect of the added stimuli.  
 
CD95 
 
Respectively to the CD95 expression, there were no significant differences in the levels 
of CD95+ cells on total CD19+ B cells and all B cell subpopulations analyzed, when 
comparing chronic RA patients with healthy controls (data not shown). 
Furthermore, no significant differences were found in CD95 MFI values on total CD19+ 
B cells and all B cell subpopulations (except in double-negative B cells) analyzed, when 
comparing chronic RA patients with healthy controls.  
Figure 46 – Expression of RANKL (MFI) cell marker on total CD19+ B cells in chronic RA patients tested 
with Media + Ethanol and Celastrol + LPS is significantly reduced in comparison to healthy controls. Data 
from flow cytometry analysis of peripheral blood B cells from chronic RA patients and healthy controls 
tested with several conditions. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Particularly, it was observed that leukocytes from chronic RA patients tested with 
Celastrol (p=0.0240) condition, had significantly increased expression of CD95 MFI cell 
marker on double-negative B cells (IgD-CD27-) in comparison to healthy controls 
(Appendix IV.30). An increasing linear trend is observed in all tested conditions, which 
leads us to assume that the significant differences observed are due to the disease phenotype 
and not to the effect of the added stimuli. 
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CHAPTER V –  
 
 
In the present study the effect of celastrol, a bioactive component of the chinese plant 
Tripterygium wilfordii, on primary human leukocytes (monocytes, granulocytes, B and T 
lymphocytes and their subsets) activation, maturation, survival and apoptosis was studied 
using peripheral blood samples collected from chronic RA patients and healthy controls.  
For this purpose, we first proceeded to the optimization of experimental conditions. 
Leukocytes from healthy controls (n=4) were incubated for different incubation times with 
celastrol and stimulated with LPS, at a range of concentrations, to assess the optimal 
compounds concentrations and duration of the incubation. After incubation, cell viability 
was assessed using alarmarBlue® by spectrophotometry assay, and an immunophenotyping 
characterization of monocytes, granulocytes, B and T cells was performed by Flow 
Cytometry. Among the tested conditions, we found that incubation for 4h with celastrol 0,3 
µM and LPS 10 μg/mL was the condition that showed less lymphocyte’s, monocyte’s and 
granulocyte’s cell death, appearing to be the best condition to be tested in the following 
experiments. Next, we studied the effect of celastrol in WBCs of the recruited chronic RA 
patients (n=5) and healthy controls (n=10), using the pre-optimized experimental conditions. 
Of note, LPS was used as a non-specific stimulant to activate the peripheral WBCs. 
 
Macrophages are a hallmark of inflammation and, the abundance of these cells in RA 
joints mirrors disease activity (Haringman JJ et al., 2005). After its activation are thought to 
be major contributors to pro-inflammatory cytokine production (Jovanovic DV et al., 1998; 
Clavel C et al., 2008) and joint destruction through osteoclastogenesis (Ma Y et al., 2005). 
These cells migrate as monocytes from peripheral blood, infiltrate and accumulate in the 
synovium (Ma Y et al., 2005), where they can be differentiated into macrophages and in 
osteoclasts (Auffray C et al., 2009; Komano Y et al., 2006; Gordon S et al., 2005). 
 In the present study, we revealed that celastrol was able to restore the frequencies of 
total CD14+ cells to basal levels in monocytes from healthy controls, but no significant 
differences were observed in chronic RA patients, maybe due to the limiting effect of LPS. 
We assumed as an incongruent data that occurred perhaps due to the occurrence of 
monocyte adhesion on cell culture plates aggravated with the LPS addition, leading a 
significant cell loss and consequently, an inconsistent analysis.  
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Shinohara S et al., showed that the expression of CD14 was upregulated on peripheral 
blood monocytes from patients with active RA (Shinohara S et al., 1992). 
In fact, in our study, when comparing healthy controls with chronic RA patients, the 
frequencies of total CD14+ cells were similar at basal levels, but increased in chronic RA 
patients when leukocytes were stimulated with LPS. However, celastrol seems to reduce the 
frequencies of total CD14+ cells in chronic RA patients. 
It should not be overlooked the limiting effect of LPS and the reduced cohort of patients 
(n=5). 
Three monocytes subpopulations, have been described in humans (Wong KL et al., 
2012). However, LPS addition led to an increased adhesion of monocytes on plate wells, and 
consequently a significant loss of cells was observed, leading to a number of inconsistent 
results in comparison to the literature. Thus, the analysis of all monocyte subpopulations 
was excluded in order not to lead to wrong interpretations. 
Additionaly, in this study we have shown a decrease in the expression of surface 
markers on monocytes, both in leukocytes from healthy controls and chronic RA patients 
tested with celastrol compound.  
Previous studies have shown that monocytes have an activated phenotype in RA with 
increased expression of several surface markers, such as CD16 (monocyte activation 
marker), HLA-DR (involved in antigen presentation to CD4+ T cells), CD86 
(costimulatory molecule of T cells) and CD115 (involved in monocyte differentiation) 
(Shinohara S et al., 1992; Kawanaka N et al., 2002; Thomas R et al., 1996; Iguchi T et al., 
1986).  
Specifically, in our study we have reported that celastrol (after LPS stimulation) was 
able to diminish both the frequencies and expression MFI levels of CD16 on total CD14+ 
cells in monocytes from healthy controls, but no significant differences were observed in 
chronic RA patients and when comparing healthy controls with chronic RA patients. 
We have shown that celastrol was able to restore the expression MFI levels of HLA-
DR on total CD14+ cells to basal levels in monocytes from healthy controls. However, no 
significant differences were observed in chronic RA patients. When comparing healthy 
controls with chronic RA patients, it was observed that the expression MFI levels of HLA-
DR on total CD14+ cells were reduced in chronic RA patients, but no effect of celastrol on 
these cells was observed. 
In addition, the frequencies and expression MFI levels of CD86 on total CD14+ cells in 
healthy controls appeared to be restored to basal levels with celastrol. However, in chronic 
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RA patients, celastrol (after LPS stimulation) was able to decrease the frequencies of CD86 
on total CD14+ cells. When comparing healthy controls with chronic RA patients, it was 
observed that the frequencies and expression MFI levels of CD86 on total CD14+ cells 
were reduced in chronic RA patients, but no effect of celastrol on these cells was observed.  
Regarding to CD115, we have reported that celastrol (after LPS stimulation) was able 
to diminish both the frequencies and expression MFI levels of CD115 on total CD14+ cells 
in healthy controls. Moreover, in chronic RA patients, celastrol was able to decrease the 
frequencies of CD115 on total CD14+ cells. However, no significant differences were 
observed when comparing healthy controls with chronic RA patients. 
 
Granulocytes are the most abundant leukocytes and include neutrophils, which are the 
first cell type to infiltrate the synovium and arrive at sites of inflammation (Nathan C et al., 
2006). In RA, the mechanisms of neutrophil activation, recruitment and apoptosis are altered 
(Weinmann P et al., 2007) and it has been described that these phagocytic cells when 
activated play a crucial role since the early phase of the disease (Cascão R et al., 2010), as 
they are able to modulate the function of other immune cells and contribute to the 
perpetuation of an initial inflammatory response. 
Granulocytes when activated express CD66b (population marker), CD11b (granulocyte 
activation marker), CD16 (involved in the immunophagocytosis; specifically, CD16high - 
nonapoptotic granulocytes), CD15 (activation and adhesion marker), CD62L (granulocyte 
adhesion marker) and CXCR2 (major granulocyte chemoattractant receptor) surface 
markers. 
Given the proposed role of granulocytes in the pathogenesis of RA, we found that the 
celastrol had no significant effect on total CD66b+ cells in granulocytes, both in healthy 
controls and chronic RA patients. When comparing healthy controls with chronic RA 
patients, it was observed that the frequencies of total CD66b+ cells were increased in 
chronic RA patients. 
In our study we have reported that celastrol was able to restore the expression MFI 
levels of CD11b on total CD66b+ cells to basal levels in granulocytes from healthy controls 
and chronic RA patients, but no significant differences were observed when comparing 
healthy controls with chronic RA patients. 
In addition, no significant differences were observed in the frequencies and expression 
MFI levels of CD16high and CD16low both in healthy controls and chronic RA patients, 
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however, when comparing healthy controls with chronic RA patients it was observed that 
the frequencies of CD16high and CD16low on total CD66b+ cells were increased and reduced, 
respectively, in chronic RA patients. 
We have shown that no significant differences were observed in the frequencies and 
expression MFI levels of CD15 both in healthy controls and chronic RA patients, however, 
when comparing healthy controls with chronic RA patients it was observed that the 
frequencies of CD15 on total CD66b+ cells were increased, in chronic RA patients, but no 
effect of celastrol on these cells was observed.. 
Regarding CD62L, we have reported that celastrol was able to diminish the expression 
MFI levels of CD62L on total CD66b+ cells in healthy controls, but no significant 
differences were observed in chronic RA patients. Morever, when comparing healthy 
controls with chronic RA patients, it was observed that the expression MFI levels of 
CD62L on total CD66b+ cells were reduced in chronic RA patients. 
Lastly, the frequencies of CXCR2 on total CD66b+ cells in healthy controls appeared to 
be restored to basal levels with celastrol, but no significant differences were observed in 
chronic RA patients. However, when comparing healthy controls with chronic RA patients, 
it was observed that the frequencies and expression MFI levels of CXCR2 on total CD66b+ 
cells were increased in chronic RA patients, but no effect of celastrol on these cells was 
observed. 
 
For a long time, RA has been considered as a T-cell driven disease (Boissier MC et al., 
2008). Reports have implicated Th17 cells as important effectors in RA pathogenesis due to 
the overexpression of IL-17, which is associated with an aggravation of inflammation and 
joint damage (Lubberts E et al., 2005; Chabaud M et al., 1999). Cytokines that support Th17 
differentiation, suppress Treg cells polarization, and consequently shift T cell homeostasis 
towards inflammation. 
In this study, we have shown that celastrol had no significant effect on total CD3+ T 
cells, both in healthy controls and chronic RA patients, not even when comparing healthy 
controls with chronic RA patients. 
In this study, the main T cell subpopulations (CD4+ and CD8+ T cells - Thelper and 
Tcytotoxic cells, respectively) and their subsets were analyzed. Several studies have 
observed reduced circulating Treg cell percentages in RA compared to healthy controls, and 
have pointed the importance of Th17/Treg cell imbalance in the pathogenesis of RA (Niu Q 
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et al., 2012; Kawashiri SY et al., 2011; Sempere-Ortells JM et al., 2009). 
Regarding to the frequencies of T cell subpopulations studied, we have reported that 
celastrol was able to restore the frequencies of naïve activated T helper cells (CD45RO-
HLA-DR+) to basal levels in T cells from healthy controls, but no significant differences 
were observed in chronic RA patients. However, when comparing healthy controls with 
chronic RA patients, it was observed that the frequencies of this population were increased 
in chronic RA patients, but no effect of celastrol on these cells was observed. 
Additionally, it was observed that celastrol had no significant effect on memory 
activated T helper cells (CD45RO+HLA-DR+) in healthy controls, but it was able to 
increase the frequencies of this subpopulation in chronic RA patients. However, no 
significant differences were observed when comparing healthy controls with chronic RA 
patients. 
We have found that celastrol had no significant effect on CD25bright Treg cells 
(CD4+CD25bright), both in healthy controls and chronic RA patients, however, when 
comparing healthy controls with chronic RA patients, it was observed that the frequencies 
of this population were increased in chronic RA patients, but no effect of celastrol on these 
cells was observed. 
Regarding to the central memory Th1-like cells (CXCR3+CCR6-), we have shown that 
celastrol had no significant effect on this subpopulation, both in healthy controls and 
chronic RA patients, however, when comparing healthy controls with chronic RA patients, 
it was observed that the frequencies of this subpopulation were increased in chronic RA 
patients, but no effect of celastrol on these cells was observed. 
In addition, the frequencies of central memory Th2-like cells (CXCR3-CCR6-) in 
healthy controls appeared to be increased with celastrol, but no significant differences were 
observed in chronic RA patients. However, when comparing healthy controls with chronic 
RA patients, it was observed that the frequencies of this subpopulation were reduced in 
chronic RA patients, but no effect of celastrol on these cells was observed.  
Also, we have found that celastrol had no significant effect on effector memory T 
helper cells (CD45RO+CCR7-), both in healthy controls and chronic RA patients, however, 
when comparing healthy controls with chronic RA patients, it was observed that the 
frequencies of this subpopulation were reduced in chronic RA patients, but no effect of 
celastrol on these cells was observed. 
We have reported that celastrol had no significant effect on effector memory Th1-like 
cells (CXCR3+CCR6-), both in healthy controls and chronic RA patients, however, when 
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comparing healthy controls with chronic RA patients, it was observed that the frequencies 
of this subpopulation were increased in chronic RA patients, but no effect of celastrol on 
these cells was observed. 
In addition, the frequencies of effector memory Th2-like cells (CXCR3-CCR6-) in 
healthy controls appeared to be increased with celastrol, but no significant differences were 
observed in chronic RA patients. However, when comparing healthy controls with chronic 
RA patients, it was observed that the frequencies of this subpopulation were reduced in 
chronic RA patients, but no effect of celastrol on these cells was observed. 
We have found that celastrol had no significant effect on effector memory Th17-like 
cells (CXCR3-CCR6+), both in healthy controls and chronic RA patients, however, when 
comparing healthy controls with chronic RA patients, it was observed that the frequencies 
of this population were reduced in chronic RA patients, but no effect of celastrol on these 
cells was observed.  
In the current study, we noticed an effect of celastrol on several cellular markers on T 
cells, concerning to the T cell activation (HLA-DR), Th17 cells differentiation (RORgT), 
suppressive activity of Treg cells (Foxp3) and chemotaxis of memory Th1 cells (CXCR3). 
Particularly, we have shown that celastrol had no significant effect in the expression 
MFI levels of HLA-DR both in healthy controls and chronic RA patients, however, when 
comparing healthy controls with chronic RA patients it was observed that the expression of 
MFI levels of HLA-DR on total CD3+ T cells and T helper (CD3+CD4+) and T cytotoxic 
(CD3+CD8+) cells were increased in chronic RA patients, but no effect of celastrol on these 
cells was observed.  
Also, we have reported that celastrol had no significant effect in the expression MFI 
levels of RORgT both in healthy controls and chronic RA patients, however, when 
comparing healthy controls with chronic RA patients it was observed that the expression of 
MFI levels of RORgT on T helper cells (CD3+CD4+) were increased in chronic RA 
patients, but no effect of celastrol on these cells was observed.  
In addition, we have found that celastrol had no significant effect in the expression MFI 
levels of Foxp3 both in healthy controls and chronic RA patients, however, when 
comparing healthy controls with chronic RA patients it was observed that the expression of 
MFI levels of Foxp3 on T reg cells (CD25+Foxp3+ subset), CD25int (CD4+CD25int) and 
CD25bright (CD4+CD25bright) Treg cells were reduced in chronic RA patients, but no effect of 
celastrol on these cells was observed. 
Among CD4+CD25+ cells, only those expressing large amounts of CD25 
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(CD4+CD25bright) exert suppressive effects. Cells expressing intermediate amounts of CD25 
(CD4+CD25int), in contrast, are effector CD4 cells (Mottonen M et al., 2005). In RA, it has 
been demonstrated that the expression of Foxp3 by Treg cells is diminished which affects 
the ability of Treg cells to suppress effector T-cell proliferation and cytokine secretion 
(Valencia X et al., 2006). 
In concordance with the literature, it was observed that Foxp3 expresssion (MFI) of 
Treg cells was significantly reduced in RA patients in comparison with healthy individuals, 
however, no effect was found when this cell population was in the presence of celastrol.  
Lastly, the expression MFI levels of CXCR3 on total CD3+ T cells and T helper cells 
(CD3+CD4+) in healthy controls appeared to be reduced with celastrol (after LPS 
stimulation), but no significant differences were observed in chronic RA patients. However, 
when comparing healthy controls with chronic RA patients, it was observed that the 
expression MFI levels of CXCR3 on total CD3+ T cells and T helper cells (CD3+CD4+) 
were increased in chronic RA patients, but no effect of celastrol on these cells was observed.  
 
Several studies have documented the importance of B cells in RA progression through 
diverse mechanisms, not only by producing and releasing autoantibodies such as RF and 
ACPA, which activate macrophages and induce production of pro-inflammatory cytokines, 
but also throug their functions as APCs for T cell activation (Smolen JS et al., 2007; Kinne 
RW et al., 2007; Weyand CM et al., 2005; Moura RA et al., 2012). 
In the present study, we found that the celastrol had no significant effect on total 
CD19+ B cells, both in healthy controls and chronic RA patients, however, when 
comparing healthy controls with chronic RA patients, it was observed that the frequencies 
of total CD19+ B cells were reduced in chronic RA patients, but celastrol did not seem to 
have significant effect on this population, since a downward linear trend was observed in all 
tested conditions, which leads us to assume that the significant differences observed are due 
to the disease phenotype/activity and not to the effect of the compound.  
The main B cell subpopulations were analyzed, depending on their IgD /CD27 and 
IgD/CD38 expression. Abnormalities in the distribution of peripheral blood B cell 
subpopulations, particularly memory B cell subsets, have been reported in RA patients 
(Moura RA et al., 2010; Souto-Carneiro MM et al., 2009). Of note, it has been previously 
shown that established RA patients have significantly lower levels of peripheral blood pre-
switch (IgD+CD27+) memory B cells (Souto-Carneiro MM et al., 2009), and significantly 
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increased levels of double-negative (IgD-CD27-) memory B cells (Moura RA et al., 2017) 
when compared to healthy controls.  
In our study, we have shown that celastrol had no significant effect in the frequencies 
of all B cell subpopulations both in healthy controls and chronic RA patients. When 
comparing healthy controls with chronic RA patients, it was observed that the frequencies 
of transitional B cells (IgD+CD38++) were reduced in chronic RA patients, but celastrol did 
not seem to have significant effect on this population, since a downward linear trend was 
observed in all tested conditions, which leads us to assume that the significant differences 
observed are due to the disease phenotype/activity and not to the effect of the compound 
In this study, several B cell markers were studied which were directly related with B 
cell activation (HLA-DR) and survival (BAFF-R), B cell adhesion, activation and calcium 
signaling (CD38), cell inhibition (FcgRIIB), complement system activation: autoimmunity-
associated marker (CD21lowCD38low) / immature B cells (CD21), osteoclast activation and 
differentiation (RANKL) and Fas-mediated apoptosis (CD95). 
Particularly, we have shown that celastrol (after LPS stimulation) was able to restore 
the frequencies of HLA-DR on transitional B cells (IgD+CD38++) to basal levels in B cells 
from healthy controls, but no significant differences were observed in chronic RA patients. 
However, when comparing healthy controls with chronic RA patients, it was observed that 
the frequencies of HLA-DR on total CD19+ B cells, pre-switch memory (IgD+CD27+) and 
post-switch memory (IgD-CD27+)  B cells (IgD+CD38++) were reduced in chronic RA 
patients, but no effect of celastrol on these cells was observed 
Previous studies have reported that B cells once activated increase the expression of 
activation markers such as HLA-DR (Feldmann M et al., 1996), in accordance with their 
function as APCs locally in the joints (Takemura S et al., 2001; Heldt C et al., 2003; Bowes 
J et al., 2008). Contrarily, in our study, it was observed a trend to reduce the HLA-DR 
frequency on transitional B cells (IgD+CD38++) when leukocytes are stimulated with LPS, 
and a restore to basal levels upon celastrol (after LPS stimulation) incubation.  
Regarding BAFF-R, celastrol had no significant effect in the frequencies and 
expression MFI levels of BAFF-R both in healthy controls and chronic RA patients. When 
comparing healthy controls with chronic RA patients it was observed that the frequencies 
of BAFF-R on total CD19+ B cells and pre-switch memory (IgD+CD27+) B cells and the 
expression MFI levels on total CD19+ B cells, naïve B cells (IgD+CD27-), pre-switch 
memory (IgD+CD27+), post-switch memory (IgD-CD27+) and double-negative (IgD-
CD27-) B cells were reduced in chronic RA patients, but no effect of celastrol on these cells 
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was observed.  
In addition, no significant differences were observed in the expression MFI levels of 
CD38 both in healthy controls and chronic RA patients, however, when comparing healthy 
controls with chronic RA patients it was observed that the expression MFI levels of CD38 
on post-switch memory (IgD-CD27+) and double-negative (IgD-CD27-) B cells were 
reduced in chronic RA patients, but no effect of celastrol on these cells was observed.  
Regarding FcgRIIB, we have observed that celastrol was able to restore the expression 
MFI levels of FcgRIIB on plasmablasts (IgD-CD38++) to basal levels in healthy controls, 
but no significant differences were observed in chronic RA patients and when comparing 
healthy controls with chronic RA patients.  
However, data have shown that peripheral B cells from RA patients have altered 
expression of FcgRIIB, potentially contributing to tolerance breakdown and development 
of humoral autoimmunity (Catalan D et al., 2010).  
Importantly, our study has not shown the same effect of celastrol on chronic RA 
patients as shown in healthy controls, possibly due to reduced cohort of patiens (n=5) 
which is not sufficient to have robust results and consistent with the literature. 
We have also reported that celastrol was able to restore the expression MFI levels of 
CD21 on total CD19+ B cells and naïve B cells (IgD+CD27-) to basal levels in healthy 
controls, but no significant differences were observed in chronic RA patients. However, 
when comparing healthy controls with chronic RA patients it was observed that the 
frequencies of CD21 on total CD19+ B cells, naïve (IgD+CD27-) and pre-switch memory 
(IgD+CD27+) B cells were reduced in chronic RA patients, and the expression levels of 
CD21 on pre-switch memory (IgD+CD27+) B cells were also reduced in chronic RA 
patients, but no effect of celastrol on these cells was observed. 
The activation of B cells leads to reduced surface levels of CD21, as it has been shown 
in peripheral blood of RA patients (Masilamani M et al., 2003). 
Importantly, we have shown that no significant differences were observed in the 
frequencies of CD21lowCD38low both in healthy controls and chronic RA patients. When 
comparing healthy controls with chronic RA patients, it was observed that the frequencies 
CD21lowCD38low on total CD19+ B cells were increased in chronic RA patients, but no 
effect of celastrol on these cells was observed. 
It has been published that B cells with low expression of CD21 (CD21low B cells) are 
increased in the peripheral blood of patients with RA (Isnardi I et al., 2010) and others 
autoimmune diseases (Wehr C et al., 2004; Nicholas MW et al., 2008), as shown in our 
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study. CD21low B cells express elevated levels of CD19 (Erickson LD et al., 2001) and low 
levels of CD38 (Danzer CP et al., 2003). Isnardi et al., found that CD21low B cells in were 
unable to induce calcium influx, become activated, or proliferate in response to B-cell 
receptor (Isnardi I et al., 2010).  
Moreover, we have shown that celastrol was able to restore the frequencies of RANKL 
on total CD19+ B cells, naïve (IgD+CD27-), pre-switch memory (IgD+CD27+), post-switch 
memory (IgD-CD27+) B cells to basal levels and diminish the frequencies of RANKL on 
transitional B cells (IgD+CD38++) in healthy controls, but no significant differences were 
observed in chronic RA patients. However, when comparing healthy controls with chronic 
RA patients it was observed that the frequencies of RANKL on post-switch memory (IgD-
CD27+) and double-negative (IgD-CD27-) B cells were increased in chronic RA patients, 
and in contrast, the expression MFI levels of RANKL on total CD19+ B cells and naïve B 
cells (IgD+CD27-) were reduced in chronic RA patients, but no effect of celastrol on these 
cells was observed. 
Regarding to CD95, we have reported that celastrol was able to restore the frequencies 
of CD95 on naïve B cells (IgD+CD27-) and plasmablasts (IgD-CD38++) and the expression 
MFI levels on plasmablasts (IgD-CD38++) to basal levels, and was also able to diminish the 
frequencies of CD95 on transitional B cells (IgD+CD38++) and the expression MFI levels 
on naïve B cells (IgD+CD27-) and transitional B cells (IgD+CD38++) in healthy controls. 
However, no significant differences were observed in chronic RA patients, but when 
comparing healthy controls with chronic RA patients it was observed that the expression 
MFI levels of CD95 on double-negative (IgD-CD27-) B cells were increased in chronic RA 
patients, but no effect of celastrol on these cells was observed. 
Importantly, defects in apoptosis, namely in the CD95-dependent death receptor 
pathway, have been demonstrated to occur in RA pathogenesis and a significant expansion 
of activated memory B cell populations expressing high levels of CD95 in the peripheral 
blood has been documented (Cantwell MJ et al., 1997; Rapetti et al., 2013). 
 
Importantly, our study has not shown the same effect of celastrol in some cases of cell 
populations on chronic RA patients as shown in healthy controls, possibly due to the 
reduced cohort of patiens (n=5) which is not sufficient to have robust and significant results 
and consistent with the literature. In addition, about monocytes, it should not be overlooked 
the limiting effect of LPS, which produced unreliable results and incongruent data that 
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occurred perhaps due to the occurrence of monocyte adhesion on cell culture plates 
aggravated with the LPS addition, leading a significant cell loss and consequently, an 
inconsistent analysis.  
Although the mechanisms of action of celastrol are not yet fully understood, this work 
brings new insights regarding to the effect of this compound on human peripheral blood 
leukocytes activation, maturation, survival and apoptosis both in healthy control and chronic 
RA patients. 
 Altogether, our data revealed that celastrol seems to have a stronger effect on innate 
immune system cells, reducing their overall activation, differentiation and migration 
potential. Importantly, this finding has implications for the selection of potential diseases 
and disease stages where this compound might be particularly effective.  
To sum up, we suggest that celastrol is a promising candidate for future clinical trials 
in RA patients and if validated, might serve as useful adjunct/alternative to conventionally 
used drugs, whose long-term use is associated with severe adverse effects. Then, we expect 
that this work can bring a new therapeutical option for patients who are refractory to 
biotechnological drugs and a higher accessibility to better care.  
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APPENDIX 
 
1. APPENDIX I  
 
1.1. MULTICOLOR FLOW CYTOMETRY PANEL 
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Mix 1 was composed by the following antibodies: CD19 PerCP-Cy5.5, CD27 eFluor450, 
IgD PE-Cy7, CD38 APC-eFluor 780, BAFF-R PE and FcgRIIB (CD32) APC. 
 Mix 2 was composed by the following antibodies: CD19 PerCP-Cy5.5, CD27 eFluor450, 
IgD PE-Cy7, CD38 APC-eFluor 780, CD21 PE and HLA-DR APC.  
Mix 3 was composed by the following antibodies: CD19 PerCP-Cy5.5, CD27 eFluor450, 
IgD PE-Cy7, CD38 APC-eFluor 780, RANKL PE and CD95 APC.  
Mix 4 was composed by the following antibodies: CD3 APC, CD4 PerCP-Cy5.5, CD45RO 
APC-eFluor 780, HLA-DR eFluor 450, CD8 PE and CD40L PE-Cy7.  
Mix 5 was composed by the following antibodies: CD3 APC, CD4 PerCP-Cy5.5, CD45RO 
APC-eFluor 780, Foxp3 eFluor 450, RORgT PE and CD25 PE-Cy7.  
Mix 6 was composed by the following antibodies: CD3 APC, CD4 PerCP-Cy5.5, CD45RO 
APC-eFluor 780, CCR7 Pacific Blue, CCR6 PE and CXCR3 PE-Cy7.  
Mix 7 was composed by the following antibodies: CD14 PerCP-Cy5.5, CD3 APC, CD16 
APC-Cy7, HLA-DR eFluor 450 and CD86 PE.  
Mix 8 was composed by the following antibodies: CD14 PerCP-Cy5.5, CD3 APC, CD16 
APC-Cy7, RANK PE and CD115 PE-Cy7.  
Mix 9 was composed by the following antibodies: CD66b PE-Cy7, CD11b PerCP-Cy5.5, 
CD16 APC-Cy7, CD15 eFluor 450, CXCR2 PE and CD62L APC. 
 
Cell surface or intracellular staining was proceed depending on the type of antibody to 
be used, being aware that antibodies such as anti- CD3 (1:20), CD4 (1:20), CD8 (1:20), 
CD11b (1:40), CD14 (1:40), CD15 (1:100), CD16 (1:40), CD19 (1:20), CD21 (1:40), CD25 
(1:40), CD27 (1:20), CD32 (FcgRIIB) (1:20), CD38 (1:40), CD40L (1:20), CD45RO (1:40)/ 
(New : 1:100), CD62-L (L-selectin) (1:40), CD66b (1:20), CD86 (1:40), CD95 (1:20), 
CD115 (1:20), CXCR2 (CD182) (1:20), CXCR3 (CD183) (1:40), CCR6 (CD196) (1:20), 
CCR7 (CD197) (1:20), BAFF-R (1:20), HLA-DR (APC - 1:20) (eF450 - 1:40), IgD (1:40), 
RANK (1:10) and RANKL (1:20) are surface antibodies and anti- Foxp3 (1:20) and RORgT 
(1:20) are intracellular antibodies. 
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2. APPENDIX II – Monocytes 
 
2.1. CELASTROL EFFECT ON MONOCYTES FROM HEALTHY CONTROLS 
 
 
 
 
 
Appendix II.1 – Frequency of classical monocytes from healthy controls is 
significantly reduced with LPS condition in comparison to Media + Ethanol, and 
significantly increased with Celastrol and Celastrol + LPS in comparison to LPS. 
Data from flow cytometry analysis of peripheral blood monocytes from healthy 
controls tested with several conditions. Classical monocytes (CD14+CD16-) were 
gated in CD14+ cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to 
the Mann-Whithey tests. 
Appendix II.2 – Frequency of intermediate monocytes from healthy controls is 
significantly reduced with LPS and Celastrol + LPS conditions in comparison to Media + 
Ethanol, also significantly reduced with Celastrol + LPS in comparison to Celastrol, and 
significantly increased with Celastrol in comparison to LPS. Data from flow cytometry 
analysis of peripheral blood monocytes from healthy controls tested with several 
conditions. Intermediate monocytes (CD14+CD16+) were gated in CD14+ cells. Data 
are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.3 – Frequency of non-classical monocytes from healthy controls is 
significantly reduced with Celastrol + LPS condition in comparison to Media + Ethanol, 
LPS and Celastrol. Data from flow cytometry analysis of peripheral blood monocytes 
from healthy controls tested with several conditions. Non-classical monocytes 
(CD14dimCD16+) were gated in CD14+ cells. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
 
Appendix II.4 – Frequency of CD86+ cells on classical monocytes from healthy 
controls is significantly reduced with LPS condition in comparison to Media + 
Ethanol, also significantly reduced with Celastrol + LPS in comparison to Media + 
Ethanol and Celastrol, and significantly increased with Celastrol in comparison to 
LPS. Data from flow cytometry analysis of peripheral blood monocytes from healthy 
controls tested with several conditions. Classical monocytes (CD14+CD16-) were 
gated in CD14+ cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to 
the Mann-Whithey tests. 
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Appendix II.5 – Frequency of CD86+ cells on non-classical monocytes from healthy controls 
is significantly reduced with LPS condition in comparison to Media + Ethanol, also 
significantly reduced with Celastrol + LPS in comparison to Media + Ethanol and Celastrol, 
significantly increased with Celastrol + LPS in comparison to LPS and significantly increased 
with Celastrol in comparison to LPS. Data from flow cytometry analysis of peripheral blood 
monocytes from healthy controls tested with several conditions. Non-classical monocytes 
(CD14dimCD16+) were gated in CD14+ cells. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to 
the Mann-Whithey tests. 
Appendix II.6 – Expression of CD86 (MFI) cell marker on classical monocytes from healthy 
controls is significantly reduced with LPS in comparison to Media + Ethanol, and also 
significantly reduced with Celastrol + LPS in comparison to Media + Ethanol and Celastrol, and 
significantly increased with Celastrol in comparison to LPS. Data from flow cytometry analysis 
of peripheral blood monocytes from healthy controls tested with several conditions. Classical 
monocytes (CD14+CD16-) were gated in CD14+ cells. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests 
Appendix II.7 – Expression of CD86 (MFI) cell marker on non-classical monocytes from healthy 
controls is significantly reduced with LPS in comparison to Media + Ethanol and also 
significantly reduced with Celastrol + LPS in comparison to Media + Ethanol. Data from flow 
cytometry analysis of peripheral blood monocytes from healthy controls tested with several 
conditions. Non-classical monocytes (CD14dimCD16+) were gated in CD14+ cells. Data are 
expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.8 – Frequency of HLA-DR+ cells on non-classical monocytes from healthy controls 
is significantly reduced with LPS condition in comparison to Media + Ethanol, also significantly 
reduced with Celastrol + LPS in comparison to Media + Ethanol, and significantly increased 
with Celastrol in comparison to LPS. Data from flow cytometry analysis of peripheral blood 
monocytes from healthy controls tested with several conditions. Non-classical monocytes 
(CD14dimCD16+) were gated in CD14+ cells. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
Appendix II.9 – Expression of HLA-DR (MFI) cell marker on classical monocytes from healthy 
controls is significantly increased with LPS in comparison to Media + Ethanol and significantly 
reduced with Celastrol + LPS in comparison to LPS. Data from flow cytometry analysis of 
peripheral blood monocytes from healthy controls tested with several conditions. Classical 
monocytes (CD14+CD16-) were gated in CD14+ cells. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix II.10 – Frequency of CD115+ cells on classical monocytes from healthy controls is 
significantly reduced with LPS, Celastrol and Celastrol + LPS conditions in comparison to 
Media + Ethanol and also significantly reduced with Celastrol + LPS in comparison to 
Celastrol. Data from flow cytometry analysis of peripheral blood monocytes from healthy 
controls tested with several conditions. Classical monocytes (CD14+CD16-) were gated in 
CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Appendix II.15 – Expression of CD115 (MFI) cell marker on non-classical monocytes from 
healthy controls is significantly reduced with LPS + Celastrol in comparison to Media + Ethanol 
and Celastrol. Data from flow cytometry analysis of peripheral blood monocytes from healthy 
controls tested with several conditions. Non-classical monocytes (CD14dimCD16+) were gated in 
CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.12 – Frequency of CD115+ cells on non-classical monocytes from healthy controls 
is significantly reduced with Celastrol + LPS condition in comparison to Media + Ethanol and 
Celastrol. Data from flow cytometry analysis of peripheral blood monocytes from healthy 
controls tested with several conditions. Non-classical monocytes (CD14dimCD16+) were gated in 
CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.11 – Frequency of CD115+ cells on intermediate monocytes from healthy controls 
is significantly reduced with Celastrol + LPS condition in comparison to Media + Ethanol, LPS 
and Celastrol. Data from flow cytometry analysis of peripheral blood monocytes from healthy 
controls tested with several conditions. Intermediate monocytes (CD14+CD16+) were gated in 
CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.13 – Expression of CD115 (MFI) cell marker on classical monocytes from healthy 
controls is significantly reduced with LPS, Celastrol and Celastrol + LPS in comparison to 
Media + Ethanol and significantly reduced with Celastrol + LPS in comparison to Celastrol. 
Data from flow cytometry analysis of peripheral blood monocytes from healthy controls 
tested with several conditions. Classical monocytes (CD14+CD16-) were gated in CD14+ 
cells. Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.14 – Expression of of CD115 (MFI) cell marker intermediate monocytes from 
healthy controls is significantly reduced with Celastrol + LPS condition in comparison to 
Media + Ethanol, LPS and Celastrol. Data from flow cytometry analysis of peripheral blood 
monocytes from healthy controls tested with several conditions. Intermediate monocytes 
(CD14+CD16+) were gated in CD14+ cells. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to 
the Mann-Whithey tests. 
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2.2. CELASTROL EFFECT ON MONOCYTES FROM CHRONIC RA PATIENTS 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II.16 – Frequency of CD86+ cells on classical monocytes from chronic RA patients is 
significantly reduced with LPS condition in comparison to Media + Ethanol, also significantly 
reduced with Celastrol + LPS in comparison to Media + Ethanol. Data from flow cytometry 
analysis of peripheral blood monocytes from chronic RA patients tested with several 
conditions. Classical monocytes (CD14+CD16-) were gated in CD14+ cells. Data are expressed 
as median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
Appendix II.17 – Frequency of CD115+ cells on classical monocytes from chronic RA patients is 
significantly reduced with Celastrol and Celastrol + LPS conditions in comparison to Media + 
Ethanol. Data from flow cytometry analysis of peripheral blood monocytes from chronic RA 
patients tested with several conditions. Classical monocytes (CD14+CD16-) were gated in 
CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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2.3. CELASTROL EFFECT ON MONOCYTES FROM CHRONIC RA PATIENTS vs 
HEALTHY CONTROLS 
 
 
 
 
 
 
 
 
 
Appendix II.18 – Frequency of classical monocytes in chronic RA patients tested with LPS and 
Celastrol is significantly increased in comparison to healthy controls. Data from flow cytometry 
analysis of peripheral blood monocytes from chronic RA patients and healthy controls tested with 
several conditions. Classical monocytes (CD14+CD16-) were gated in CD14+ cells. Data are 
expressed as median with interquartile range. Differences were considered statistically significant 
for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.19 – Frequency of non-classical monocytes in chronic RA patients tested with Media + 
Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy 
controls. Data from flow cytometry analysis of peripheral blood monocytes from chronic RA 
patients and healthy controls tested with several conditions. Non-classical monocytes 
(CD14dimCD16+) were gated in CD14+ cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Appendix II.21 – Expression of CD86 (MFI) cell marker on classical monocytes in chronic 
RA patients tested with Media + Ethanol, Celastrol and Celastrol + LPS is significantly 
reduced in comparison to healthy controls. Data from flow cytometry analysis of 
peripheral blood monocytes from chronic RA patients and healthy controls tested with 
several conditions. Classical monocytes (CD14+CD16-) were gated in CD14+ cells. Data are 
expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.20 – Frequency of CD86+ cells on classical monocytes in chronic RA 
patients tested with Media + Ethanol, Celastrol and Celastrol + LPS is significantly 
reduced in comparison to healthy controls. Data from flow cytometry analysis of 
peripheral blood monocytes from chronic RA patients and healthy controls tested with 
several conditions. Classical monocytes (CD14+CD16-) were gated in CD14+ cells. Data 
are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Appendix II.24 – Expression of CD115 (MFI) cell marker on non-classical monocytes in chronic 
RA patients tested with Celastrol is significantly reduced in comparison to healthy controls. 
Data from flow cytometry analysis of peripheral blood monocytes from chronic RA patients and 
healthy controls tested with several conditions. Non-classical monocytes (CD14dimCD16+) were 
gated in CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
 
Appendix II.25 – Frequency of RANK+ cells on non-classical monocytes in chronic RA patients 
tested with Celastrol + LPS is significantly reduced in comparison to healthy controls. Data 
from flow cytometry analysis of peripheral blood monocytes from chronic RA patients and 
healthy controls tested with several conditions. Non-classical monocytes (CD14dimCD16+) were 
gated in CD14+ cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix II.22 – Expression of HLA-DR (MFI) cell marker on classical monocytes in chronic RA 
patients tested with Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood monocytes 
from chronic RA patients and healthy controls tested with several conditions. Classical monocytes 
(CD14+CD16-) were gated in CD14+ cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Appendix II.23 – Frequency of CD115+ cells on non-classical monocytes in chronic RA patients 
tested with Celastrol is significantly reduced in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood monocytes from chronic RA patients and healthy controls 
tested with several conditions. Non-classical monocytes (CD14dimCD16+) were gated in CD14+ 
cells. Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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3. APPENDIX III – T cells 
 
3.1. CELASTROL EFFECT ON T CELLS FROM HEALTHY CONTROLS 
 
 
 
 
 
 
 Appendix III.1 – Frequency of naïve activated T helper cells from healthy controls is significantly reduced with Celastrol condition in comparison to LPS and significantly 
increased with Celastrol + LPS in comparison to Media + Ethanol and Celastrol. Data from 
flow cytometry analysis of peripheral blood T cells from healthy controls tested with 
several conditions. Naïve activated T helper cells (CD45RO-HLA-DR+) were gated in 
CD3+CD4+ T cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix III.2 – Frequency of central memory Th2-like cells from healthy controls is 
significantly increased with Celastrol condition in comparison to Media + Ethanol and LPS, 
and also significantly increased with Celastrol + LPS in comparison to Media + Ethanol and 
LPS. Data from flow cytometry analysis of peripheral blood T cells from healthy controls 
tested with several conditions. Central memory Th2-like cells (CD45RO+CCR7+CXCR3-CCR6-
) were gated in CD3+CD4+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
Appendix III.3 – Frequency of effector memory Th2-like cells from healthy controls is 
significantly increased with Celastrol condition in comparison to Media + Ethanol and also 
significantly increased with Celastrol + LPS in comparison to Media + Ethanol and LPS. Data 
from flow cytometry analysis of peripheral blood T cells from healthy controls tested with 
several conditions. Effector memory Th2-like cells (CD45RO+CCR7-CXCR3-CCR6-) were 
gated in CD3+CD4+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
Appendix III.4 – Expression of CXCR3 (MFI) cell marker on T helper cells from healthy 
controls is significantly reduced with Celastrol + LPS in comparison to Media + Ethanol and 
LPS. Data from flow cytometry analysis of peripheral blood T cells from healthy controls 
tested with several conditions. T helper cells (CD3+CD4+) were gated in CD3+ T cells. Data 
are expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
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3.2. CELASTROL EFFECT ON T CELLS FROM CHRONIC RA PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix III.5 – Frequency of memory activated T helper cells from chronic RA patients is 
significantly increased with Celastrol + LPS condition in comparison to Media + Ethanol. Data 
from flow cytometry analysis of peripheral blood T cells from chronic RA patients tested with 
several conditions. Memory activated T helper cells (CD45RO+HLA-DR+) were gated in 
CD3+CD4+ T cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
128 
 
3.3. CELASTROL EFFECT ON T CELLS FROM CHRONIC RA PATIENTS vs 
HEALTHY CONTROLS 
 
 
 
 
 
 
 
Appendix III.6 – Frequency of naïve activated T helper cells in chronic RA patients tested with Celastrol 
is significantly increased in comparison to healthy controls. Data from flow cytometry analysis of 
peripheral blood T cells from chronic RA patients and healthy controls tested with several conditions. 
Naïve activated T helper cells (CD45RO-HLA-DR+) were gated in CD3+CD4+ T cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix III.7 – Frequency of CD25bright regulatory T cells in chronic RA patients tested with Celastrol is 
significantly increased in comparison to healthy controls. Data from flow cytometry analysis of peripheral 
blood T cells from chronic RA patients and healthy controls tested with several conditions. CD25bright 
regulatory T cells (CD4+CD25bright) were gated in CD3+CD4+ T cells. Data are expressed as median with 
interquartile range. Differences were considered statistically significant for p-values<0.05 according to 
the Mann-Whithey tests. 
Appendix III.8 – Frequency of effector memory T helper cells in chronic RA patients tested with 
Media + Ethanol and Celastrol is significantly reduced in comparison to healthy controls. Data 
from flow cytometry analysis of peripheral blood T cells from chronic RA patients and healthy 
controls tested with several conditions. Effector memory T helper cells (CD45RO+CCR7-) were 
gated in CD3+CD4+ T cells. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
 
Appendix III.9 – Frequency of central memory Th1-like cells in chronic RA patients tested with 
Celastol and Celastrol + LPS is significantly increased in comparison to healthy controls. Data from 
flow cytometry analysis of peripheral blood T cells from chronic RA patients and healthy controls 
tested with several conditions. Central memory Th1-like cells (CD45RO+CCR7+CXCR3+CCR6-) were 
gated in CD3+CD4+ T cells. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Appendix III.14 – Expression of HLA-DR (MFI) cell marker on T helper cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly increased in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood T cells 
from chronic RA patients and healthy controls tested with several conditions. T helper cells 
(CD3+CD4+) were gated in CD3+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Appendix III.15 – Expression of HLA-DR (MFI) cell marker on T cytotoxic cells in chronic RA 
patients tested with Media + Ethanol, Celastrol and Celastrol + LPS is significantly increased in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood T cells 
from chronic RA patients and healthy controls tested with several conditions. T cytotoxic cells 
(CD3+CD8+) were gated in CD3+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Appendix III.11 – Frequency of effector memory Th1-like cells in chronic RA patients 
tested with LPS, Celastol and Celastrol + LPS is significantly increased in comparison to 
healthy controls. Data from flow cytometry analysis of peripheral blood T cells from 
chronic RA patients and healthy controls tested with several conditions. Effector 
memory Th1-like cells (CD45RO+CCR7-CXCR3+CCR6-) were gated in CD3+CD4+ T cells. 
Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix III.10 – Frequency of central memory Th2-like cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood T 
cells from chronic RA patients and healthy controls tested with several conditions. 
Central memory Th2-like cells (CD45RO+CCR7+CXCR3-CCR6-) were gated in CD3+CD4+ T 
cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
Appendix III.13 – Frequency of effector memory Th17-like cells in chronic RA patients tested 
with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in comparison 
to healthy controls. Data from flow cytometry analysis of peripheral blood T cells from chronic 
RA patients and healthy controls tested with several conditions. Effector memory Th17-like 
cells (CD45RO+CCR7-CXCR3-CCR6+) were gated in CD3+CD4+ T cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
Appendix III.12 – Frequency of effector memory Th2-like cells in chronic RA patients tested 
with Celastrol + LPS is significantly reduced in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood T cells from chronic RA patients and healthy controls 
tested with several conditions. Effector memory Th2-like cells (CD45RO+CCR7-CXCR3-CCR6-) 
were gated in CD3+CD4+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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Appendix III.20 – Expression of CXCR3 (MFI) cell marker on T helper cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly increased in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood T cells from 
chronic RA patients and healthy controls tested with several conditions. T helper cells (CD3+CD4+) 
were gated in CD3+ T cells Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix III.18 – Expression of Foxp3 (MFI) cell marker on CD25int regulatory T cells in chronic RA 
patients tested with Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood T cells from 
chronic RA patients and healthy controls tested with several conditions. CD25int regulatory T cells 
(CD4+CD25int) were gated in CD3+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
Appendix III.19 – Expression of Foxp3 (MFI) cell marker on CD25bright regulatory T cells in chronic RA 
patients tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood T cells from 
chronic RA patients and healthy controls tested with several conditions. CD25bright regulatory T cells 
(CD4+CD25bright) were gated in CD3+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
Appendix III.16 – Expression of RORgT (MFI) cell marker on T helper cells in chronic RA patients 
tested with Celastrol and Celastrol + LPS is significantly increased in comparison to healthy 
controls. Data from flow cytometry analysis of peripheral blood T cells from chronic RA patients 
and healthy controls tested with several conditions. T helper cells (CD3+CD4+) were gated in CD3+ 
T cells. Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
 
Appendix III.17 – Expression of Foxp3 (MFI) cell marker on regulatory T cells in chronic RA patients 
tested with Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to 
healthy controls. Data from flow cytometry analysis of peripheral blood T cells from chronic RA 
patients and healthy controls tested with several conditions. Regulatory T cells (CD25+Foxp3+ 
subset) were gated in CD3+ T cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
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4. APPENDIX IV – B cells 
 
4.1. CELASTROL EFFECT ON B CELLS FROM HEALTHY CONTROLS 
 
 
 
 
 
 
 
Appendix IV.1 – Expression of FcgRIIB (MFI) cell marker on plasmablasts from healthy 
controls is significantly reduced with Celastrol and Celastrol + LPS conditions in 
comparison to LPS. Data from flow cytometry analysis of peripheral blood B cells from 
healthy controls tested with several conditions. Plasmablasts (IgD-CD38++) were gated 
in CD19+ B cells. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Appendix IV.2 – Expression of CD21 (MFI) cell marker on naïve B cells from healthy 
controls is significantly increased with Celastrol condition in comparison to LPS. Data 
from flow cytometry analysis of peripheral blood B cells from healthy controls tested 
with several conditions. Naïve B cells (IgD+CD27-) were gated in CD19+ B cells. Data are 
expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests 
Appendix IV.3 – Frequency of HLA-DR+ cells on transitional B cells from healthy 
controls is significantly increased with Celastrol + LPS condition in comparison to LPS. 
Data from flow cytometry analysis of peripheral blood B cells from healthy controls 
tested with several conditions. Transitional B cells (IgD+CD38++) were gated in CD19+ 
B cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
Appendix IV.4 – Frequency of RANKL+ cells on naïve B cells from healthy controls is 
significantly increased with Celastrol condition in comparison to LPS. Data from flow 
cytometry analysis of peripheral blood B cells from healthy controls tested with 
several conditions. Naïve B cells (IgD+CD27-) were gated in CD19+ B cells. Data are 
expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Appendix IV.5 – Frequency of RANKL+ cells on pre-switch memory B cells from healthy 
controls is significantly reduced with Celastrol condition in comparison to LPS. Data 
from flow cytometry analysis of peripheral blood B cells from healthy controls tested 
with several conditions. Pre-switch memory B cells (IgD+CD27+) were gated in CD19+ B 
cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
Appendix IV.6– Frequency of RANKL+ cells on post-switch memory B cells from healthy 
controls is significantly reduced with Celastrol condition in comparison to LPS. Data 
from flow cytometry analysis of peripheral blood B cells from healthy controls tested 
with several conditions. Post--switch memory B cells (IgD-CD27+) were gated in CD19+ 
B cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey 
tests. 
Appendix IV.7– Frequency of RANKL+ cells on transitional B cells from healthy controls is 
significantly reduced with Celastrol condition in comparison to Media + Ethanol and LPS. 
Data from flow cytometry analysis of peripheral blood B cells from healthy controls tested 
with several conditions. Transitional B cells (IgD+CD38++) were gated in CD19+ B cells. 
Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.8 – Frequency of CD95+ cells on naïve B cells from healthy controls is 
significantly reduced with Celastrol condition in comparison to LPS. Data from flow 
cytometry analysis of peripheral blood B cells from healthy controls tested with several 
conditions. Naïve B cells (IgD+CD27-) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
Appendix IV.9 – Frequency of CD95+ cells on transitional B cells from healthy controls is 
significantly reduced with Celastrol condition in comparison to Media + Ethanol and LPS. 
Data from flow cytometry analysis of peripheral blood B cells from healthy controls tested 
with several conditions. Transitional B cells (IgD+CD38++) were gated in CD19+ B cells. Data 
are expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.10 – Frequency of CD95+ cells on plasmablasts from healthy controls is 
significantly reduced with Celastrol condition in comparison to LPS. Data from flow 
cytometry analysis of peripheral blood B cells from healthy controls tested with several 
conditions. Plasmablasts (IgD-CD38++) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
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Appendix IV.13 – Expression of CD95 (MFI) cell marker on plasmablasts from healthy controls 
is significantly increased with LPS in comparison to Media + Ethanol and is significantly 
reduced with Celastrol in comparison to LPS. Data from flow cytometry analysis of peripheral 
blood B cells from healthy controls tested with several conditions. Plasmablasts (IgD-CD38++) 
were gated in CD19+ B cells. Data are expressed as median with interquartile range. 
Differences were considered statistically significant for p-values<0.05 according to the Mann-
Whithey tests. 
Appendix IV.11 – Expression of CD95 (MFI) cell marker on naïve B cells from healthy controls 
is significantly reduced with Celastrol condition in comparison to Media + Ethanol. Data from 
flow cytometry analysis of peripheral blood B cells from healthy controls tested with several 
conditions. Naïve B cells (IgD+CD27-) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
Appendix IV.12 – Expression of CD95 (MFI) cell marker on transitional B cells from healthy 
controls is significantly reduced with Celastrol and Celastrol + LPS conditions in comparison to 
Media + Ethanol. Data from flow cytometry analysis of peripheral blood B cells from healthy 
controls tested with several conditions. Transitional B cells (IgD+CD38++) were gated in 
CD19+ B cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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4.2. CELASTROL EFFECT ON B CELLS FROM CHRONIC RA PATIENTS vs 
HEALTHY CONTROLS 
 
  
 
 
 
 
 
 
Appendix IV.14 – Frequency of transitional B cells in chronic RA patients tested with LPS, Celastrol 
and Celastrol + LPS is significantly reduced in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood B cells from chronic RA patients and healthy controls 
tested with several conditions. Transitional B cells (IgD+CD38++) were gated in CD19+ B cells. Data 
are expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.15 – Frequency of BAFF-R+ cells on pre-switch memory B cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood B cells 
from chronic RA patients and healthy controls tested with several conditions. Pre-switch memory 
B cells (IgD+CD27+) were gated in CD19+ B cells. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
Appendix IV.16 – Expression of BAFF-R (MFI) cell marker on naïve B cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood B cells from 
chronic RA patients and healthy controls tested with several conditions. Naïve B cells (IgD+CD27-) 
were gated in CD19+ B cells. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.17 – Expression of BAFF-R (MFI) cell marker on pre-switch memory B cells in chronic 
RA patients tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced 
in comparison to healthy controls. Data from flow cytometry analysis of peripheral blood B cells 
from chronic RA patients and healthy controls tested with several conditions. Pre-switch memory B 
cells (IgD+CD27+) were gated in CD19+ B cells. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
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Appendix IV.22 – Frequency of CD21+ cells on naïve B cells in chronic RA patients tested with 
Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy 
controls. Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients 
and healthy controls tested with several conditions. Naïve B cells (IgD+CD27-) were gated in 
CD19+ B cells. Data are expressed as median with interquartile range. Differences were 
considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.23 – Frequency of CD21+ cells on pre-switch memory B cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol and Celastrol + LPS is significantly 
reduced in comparison to healthy controls. Data from flow cytometry analysis of peripheral 
blood B cells from chronic RA patients and healthy controls tested with several conditions. Pre-
switch memory B cells (IgD+CD27+) were gated in CD19+ B cells. Data are expressed as median 
with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix IV.18 – Expression of BAFF-R (MFI) cell marker on post-switch memory B cells in 
chronic RA patients tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly 
reduced in comparison to healthy controls. Data from flow cytometry analysis of peripheral 
blood B cells from chronic RA patients and healthy controls tested with several conditions. Post-
switch memory B cells (IgD-CD27+) were gated in CD19+ B cells. Data are expressed as median 
with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix IV.19 – Expression of BAFF-R (MFI) cell marker on double-negative B cells in chronic RA 
patients tested with Media + Ethanol, LPS and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood B cells 
from chronic RA patients and healthy controls tested with several conditions. Double-negative B 
cells (IgD-CD27-) were gated in CD19+ B cells. Data are expressed as median with interquartile 
range. Differences were considered statistically significant for p-values<0.05 according to the 
Mann-Whithey tests. 
Appendix IV.20 – Expression of CD38 (MFI) cell marker on post-switch memory B cells in chronic RA 
patients tested with LPS and Celastrol is significantly reduced in comparison to healthy controls. Data 
from flow cytometry analysis of peripheral blood B cells from chronic RA patients and healthy controls 
tested with several conditions. Post-switch memory B cells (IgD-CD27+) were gated in CD19+ B cells. 
Data are expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.21 – Expression of CD38 (MFI) cell marker on double-negative B cells in chronic RA 
patients tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in 
comparison to healthy controls. Data from flow cytometry analysis of peripheral blood B cells from 
chronic RA patients and healthy controls tested with several conditions. Double-negative B cells (IgD-
CD27-) were gated in CD19+ B cells. Data are expressed as median with interquartile range. Differences 
were considered statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
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Appendix IV.24 – Expression of CD21 (MFI) cell marker on pre-switch memory B cells in chronic RA patients 
tested with Media + Ethanol, LPS, Celastrol and Celastrol + LPS is significantly reduced in comparison to 
healthy controls. Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients and 
healthy controls tested with several conditions. Pre-switch memory B cells (IgD+CD27+) were gated in CD19+ 
B cells. Data are expressed as median with interquartile range. Differences were considered statistically 
significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.25 – Frequency of HLA-DR+ cells on pre-switch memory B cells in chronic RA patients tested 
with Media + Ethanol, LPS and Celastrol and Celastrol + LPS is significantly reduced in comparison to 
healthy controls. Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients 
and healthy controls tested with several conditions. Pre-switch memory B cells (IgD+CD27+) were gated in 
CD19+ B cells. Data are expressed as median with interquartile range. Differences were considered 
statistically significant for p-values<0.05 according to the Mann-Whithey tests. 
Appendix IV.26 – Frequency of HLA-DR+ cells on post-switch memory B cells in chronic RA patients 
tested with Celastrol is significantly reduced in comparison to healthy controls. Data from flow cytometry 
analysis of peripheral blood B cells from chronic RA patients and healthy controls tested with several 
conditions. Post-switch memory B cells (IgD-CD27+) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix IV.27 – Frequency of RANKL+ cells on post-switch memory B cells in chronic RA patients tested 
with Celastrol is significantly increased in comparison to healthy controls. Data from flow cytometry 
analysis of peripheral blood B cells from chronic RA patients and healthy controls tested with several 
conditions. Post-switch memory B cells (IgD-CD27+) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix IV.28 – Frequency of RANKL+ cells on double-negative B cells in chronic RA patients tested 
with Celastrol is significantly increased in comparison to healthy controls. Data from flow cytometry 
analysis of peripheral blood B cells from chronic RA patients and healthy controls tested with several 
conditions. Double-negative B cells (IgD-CD27-) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
Appendix IV.29 – Expression of RANKL (MFI) cell marker on naïve B cells in chronic RA patients tested with 
Media + Ethanol, Celastrol and Celastrol + LPS is significantly reduced in comparison to healthy controls. 
Data from flow cytometry analysis of peripheral blood B cells from chronic RA patients and healthy 
controls tested with several conditions. Naïve B cells (IgD+CD27-) were gated in CD19+ B cells. Data are 
expressed as median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
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Appendix IV.30 – Expression of CD95 (MFI) cell marker on double-negative B cells in chronic RA patients 
tested with Media + Ethanol is significantly reduced in comparison to healthy controls. Data from flow 
cytometry analysis of peripheral blood B cells from chronic RA patients and healthy controls tested with 
several conditions. Double-negative B cells (IgD-CD27-) were gated in CD19+ B cells. Data are expressed as 
median with interquartile range. Differences were considered statistically significant for p-values<0.05 
according to the Mann-Whithey tests. 
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5. APPENDIX V  
 
5.1. LEUKOCYTES VIABILITY AFTER IN VITRO TEST OF CELASTROL – 
AlamarBlue® assay 
 
 
 
 
 
 
 
Appendix V.1 – Leucokytes viability after in vitro test of celastrol. Cell viability analysis by alarmarBlue® assay. (A) 
Healthy controls, n=10. (B) Chronic RA patients, n=5. (C) Chronic RA patients vs Healthy controls. There were no 
statistically significant differences (p<0.05) in cell viability between the tested experimental conditions, either in healthy 
controls, chronic RA patients or healthy controls vs chronic RA patients. Thus, these data indicate that the optimized 
experimental se-tup does not affect the results of the experiment. Both the addition of the LPS stimulus, celastrol and 
media maintain cell viability in the same range (above 80%, 90% viability). Data from the alarmarBlue® cell viability 
assay. Data are expressed as median with interquartile range. Differences were considered statistically significant for p-
values<0.05 according to the Mann-Whithey tests. 
A B 
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